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Abstract 
Chronic kidney disease (CKD) is characterized by a progressive and irreversible decline in 
renal function. Patients are at high risk for adverse drug events since they are typically 
administered multiple medications concurrently and pharmacokinetic changes in the diseased 
state are relatively unexplored. Recent studies point towards molecules known as uremic 
toxins for playing a mechanistic role in altering the expression and function of drug 
metabolizing enzymes and drug transporter proteins. To further investigate this hypothesis, 
an adenine-induced model of CKD was used in male wistar rats. AST-120 was administered 
to remove uremic toxins in an attempt to recover metabolic enzyme as well as transporter 
protein function and activity. Animals were injected with rosuvastatin prior to sacrifice as a 
probe for transporter function. Impaired organic anion transporting polypeptide (OATP) and 
cytochrome P450 (CYP) function are important to acknowledge in a clinical setting since 
both of these protein superfamilies have broad substrate specificities. We have shown 
significant down regulation in CYP2B1 activity and expression in rats (P<0.05); CYP2B6 is 
the human ortholog and it plays a crucial role in phase one drug metabolism. If function is 
affected, clearance for a particular class of drug (ex. statins for OATPs or bupropion for 
CYP2B6) could be altered which will affect drug efficacy and toxicity.  
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Chapter 1  
1 Introduction 
The kidneys are vital organs whose responsibilities are vast and essential to 
maintain homeostasis for several physiological processes. The most important functions 
of the kidneys are the filtration of blood, production of hormones (e.g. erythropoietin), 
regulation of blood pressure, clearance of toxins and xenobiotics, as well as regulating 
homeostasis through the body’s water and salt balance. The functional unit of the kidney 
is called the nephron and each adult human kidney contains approximately one million 
nephrons. The nephron consists of a series of tubules that filter fluid that arrives as blood 
at the glomerulus and eventually leaving in the collecting ducts as urine. The gross 
anatomical divisions of the kidney divide it into the superficial cortex (outer layer), renal 
medulla, and the renal pelvis. The flow of filtrate goes from superficial to internal, 
concentrating the fluid according to the body’s water needs. Two categories of nephron 
exist, and can be classified as either cortical or juxtamedullary depending on their length. 
Although both cortical and juxtamedullary nephrons perform similar functions, the latter 
have longer loops of henle, providing an apparatus for the body to produce highly 
concentrated urine. The components of the nephron include the glomerulus, proximal 
convoluted tubule, loop of henle, distal convoluted tubule, and the collecting duct 
(Marieb et al., 2012).  
The glomerulus is a fenestrated group of capillaries supplied by the afferent 
arteriole and emptied by the efferent arteriole. It is located within the Bowman’s capsule 
and this allows solutes and fluid to be filtered out of the blood and into the renal tubules.  
The proximal convoluted tubule is important for its absorption and secretion functions. 
The reabsorption of sodium and water both occur here, as well as the near-complete 
reabsorption of glucose. Many drugs are secreted back in this region including 
methotrexate and penicillin. The loop of henle has two distinct regions comprised by the 
descending and ascending segments of the loop. Using a counter-current gradient it 
drives water reabsorption in the descending loop and ion (e.g. sodium, potassium, 
calcium) reabsorption in the subsequent ascending loop. The distal convoluted tubule is  
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Figure 1.1 - Schematic representation of gross renal anatomy (A) and the nephron (B). 
CRV – Cortical Radiate Vein, CRA – Cortical Radiate Artery. Images were modified 
from Servier Medical Art (http://www.servier.co.uk/medical-art-gallery). 
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an important site for calcium reabsorption and also plays a vital role in the hormone-
regulated reabsorption of water. The other major tubular section for hormone inducible 
water reabsorption is the collecting duct. It is normally responsible for around 5% of 
water reabsorption but in a dehydrated state this can jump to 24% when its aquaporin 
channels are induced by anti-diuretic hormone (Marieb et al., 2012).  
A particularly important region for the regulation of blood pressure is the 
juxtaglomerular apparatus. It is located in a specialized area where the afferent and 
efferent arterioles meet the thick ascending limb of the loop of henle. Contained within it 
are granular juxtaglomerular cells, which have the ability to secrete renin, a hormone that 
catalyzes the rate limiting step in angiotensin II formation. The renin-angiotensin 
mechanism initiates the release of aldosterone, which causes water retainment secondary 
to increased sodium absorption, which will in turn increase blood volume and pressure. 
Macula densa cells are adjacent to this and provide chemoreceptors that monitor solute 
concentrations of the renal filtrate. It maintains homeostatic solute and electrolyte 
concentrations by signalling for renin release when concentrations fall below desired 
levels. There are also extraglomerular mesangial cells within this region that have 
contractile properties, and in conjunction to interactions with the macula densa and 
granular cells, they are responsible for the blood pressure regulation (Marieb et al., 
2012). 
1.1 Chronic Kidney Disease 
1.1.1 Prevalence and Diagnosis 
Chronic Kidney Disease (CKD) is a debilitating disease that affects 10-15% of 
Canadians (Coresh et al., 2007; Arora et al., 2013). CKD is described as a progressive 
decline in renal function or pathological structural changes to the kidneys that have 
persisted for over 3 months (National Kidney Foundation, 2002; Stevens and Levey, 
2009; KDIGO, 2013). It is diagnosed using urinary albumin which is a marker of kidney 
damage, or estimated glomerular filtration rate (eGFR), with the latter considered the 
most accurate method (National Kidney Foundation, 2002; Filler et al., 2014). eGFR is a 
proxy for kidney function as it estimates the flow-rate of blood being filtered by the 
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kidney (National Kidney Foundation, 2002). Determination of eGFR can be assessed by 
measuring urinary creatinine clearance levels over 24 hours or by the measurement of 
serum creatinine and application of GFR predicition equations (National Kidney 
Foundation, 2002). Two equations are used in clinical practice to estimate GFR based on 
standardized creatinine clearance, the Modification of Diet in Renal Disease Study 
equation and a more recent one from the CKD-Epidemiology Collaboration which is 
more accurate at higher filtration rates (>60ml/min/1.73m2) (Levey et al., 1999; 2009; 
Dias et al., 2013). Inulin and its analogue sinistrin may also be injected to assess renal 
function as their clearance is proportional to glomerular filtration; however they are not 
secreted in the nephron tubules and therefore provide the gold standard in accuracy for 
GFR estimation (National Kidney Foundation, 2002; Filler et al., 2014). If a diminished 
eGFR is present for more than 3 months, then a diagnosis of CKD is warranted (National 
Kidney Foundation, 2002).  
1.1.2 Stages 
Functional thresholds define the 5 different stages of CKD (Table 1.1). 
Approximately 10% of Canadians have stage 1 or 2 CKD while 3% are in stage 3 to 5 
(Arora et al., 2013). Patients in stages 1-3 have close to normal physiology with slight 
abnormalities in kidney structure or urine content, increasing to moderate reduction in 
renal function as the disease progresses (National Kidney Foundation, 2002). At this 
point treatment is centered around mitigating the progression to later stages through 
controlling blood pressure and other risk factors such as hyperglycemia and 
cardiovascular disease (National Kidney Foundation, 2002). Glomerular filtration rate for 
these stages are >90, 60-89, and 30-59ml/min/1.73m2 (1.73m2 corrects for average adult 
body surface area) for stages 1 to 3 respectively (National Kidney Foundation, 2002). 
When eGFR drops below 30ml/min/1.73m2 it is considered severe (stage 4) and 
management consists of preparing the patient for stage 5 (National Kidney Foundation, 
2002). An eGFR <15ml/min/1.73m2 results in the diagnosis of kidney failure and is also 
termed end-stage renal disease (ESRD) (National Kidney Foundation, 2002). Renal 
replacement therapy is required for treatment of symptoms at this point. Kidney allograft  
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Table 1.1 - Stages and prevalence of chronic kidney disease in North America 
Stage GFR 
(mL/min/1.
73m2) 
Description Prevalence in 
North America 
(Canadian 
bolded) 
Course of Action 
1 ≥90 Kidney 
damage with 
normal or ↑ 
GFR 
9.4% (stages 1-
2)1 
3.23% of 
Americans2 
Diagnosis and treatment of 
co-morbid conditions 
Slow progression 
2 60-89 Kidney 
damage with 
mild ↓ GFR 
3.7% of 
Americans2 
Estimating progression 
3 30-59 Moderate ↓ 
GFR 
3.1% (Stages 3-
5)1 
7.85% of 
Americans2 
Evaluate and treat 
complications 
4 15-29 Severe ↓ GFR 0.44% of 
Americans2 
Prepare for renal 
replacement 
5 <15 Kidney failure 
(ESRD) 
0.2% of 
Americans3 
Renal replacement therapy 
required 
Adapted from (Naud et al., 2012) with data from 1Arora 2013, 2National health and 
Nutrition Examination Survey (NHANES) 2007-2014, and 3United States Renal Data 
System (USRDS 2015). 
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transplantation is the gold standard renal replacement method; however it is not 
particularly accessible due to the lack of available organs. This results in most patients 
being initiated on a dialysis regimen to supplement whatever residual kidney function 
remains. 
1.1.3 Treatment 
Prior to the need for renal replacement, management of CKD is centered around 
slowing the progression and treating comorbidities. Drugs such as angiotensin converting 
enzyme inhibitors and angiotensin II receptor blockers have been shown to slow the 
progression to ESRD while drugs such as statins and beta-blockers reduce all-cause 
mortality in CKD patients (Qaseem et al., 2013). Erythropoietin replacement, 
hypoglycemic agents, vitamin D, diuretics, and drugs to balance electrolytes such as 
phosphate binders are also commonly prescribed to CKD patients. Renal replacement 
therapy largely consists of dialysis regimens as there is a long wait for transplantation. 
There are two common dialysis modalities, hemodialysis and peritoneal dialysis (PD). 
Hemodialysis consists of connecting a catheter or fistula between an artery and a vein in 
an extremity to a pump that directs blood flow through a dialyzer. This filters the 
patient’s blood extracorporeally through a semi-permeable membrane with concomitant 
counter-current dialysate flow, which removes excess fluid and toxins that would 
normally be cleared by the kidneys. Patients typically require 3-4 hour sessions 3 times a 
week to account for lost kidney function. High-flux dialysis membranes are now the 
standard of care in treatment, they have larger pores in the semi-permeable membrane, 
allowing for the removal of larger ‘middle’ molecules. The composition of the dialysate 
is a physiological saline solution that is tailored to resupply low electrolytes and to 
remove molecules that are in excess (Locatelli et al., 2015). The success of dialysis 
treatment is largely dependent on the contents of the dialysate. Patients who undergo 
dialysis treatment will still experience life-threatening signs and symptoms due to the 
imperfect nature of current dialysis regimens, this condition is distinct from uremia and 
has been named residual syndrome (Depner, 2001; Dobre et al., 2013).  
Peritoneal dialysis is divided into two main types, automated peritoneal and 
continuous ambulatory peritoneal dialysis (CAPD). CAPD involves the administration of 
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dialysate directly into the peritoneum and abdominal cavity via a surgically placed 
catheter. It requires exchange with fresh fluid 3 to 5 times per day, requiring less than 30 
minutes per exchange (Tucker et al., 1991). CAPD restores some patient autonomy and 
may be preferred by more able-bodied CKD patients (Tucker et al., 1991). Automated 
peritoneal dialysis (also known as nocturnal intermittent peritoneal dialysis; NIPD) 
normally occurs overnight and employs a mechanized device to aid in fluid exchange 
(Kathuria and Twardowski, 2000). The dialysate is normally drained and delivered 
nocturnally (Kathuria and Twardowski, 2000). NIPD can also be supplemented into a 
CAPD regime if the need arises (Kathuria and Twardowski, 2000). In 2008 only 11% of 
Canadian ESRD patients were receiving peritoneal dialysis, while 48% were on 
hemodialysis and the remaining 41% had a functional kidney transplant (CORR 2011). 
These numbers are interesting as many studies have compared the different dialysis 
modalities and have found no appreciable differences in regards to quality of life and 
survival (Tucker et al., 1991; Mehrotra et al., 2011).  
1.1.4 Etiology and Comorbidities 
Incidence of CKD is increasing as the prevalence of risk factors is steadily rising 
globally (Coresh et al., 2007; Arora et al., 2013). In 2002 the estimated global population 
on dialysis was 1.1 million with an expected 7% increase annually (Jha et al., 2012). 
Mortality in CKD is most commonly associated with comorbidities that patients are 
prone to developing as opposed to the renal damage itself. Diabetes, obesity, 
hypertension, and cardiovascular disease (CVD) are accepted as the leading causes of 
CKD as well as significant comorbidities (Coresh et al., 2007). Certain toxins, immune 
responses, HIV, obstructions to the ureters and renal tubules such as nephroliths, and HIV 
associated nephropathy are also capable of initiating renal insults which can progress to 
CKD (Hewitson et al., 2008; Levey and Coresh, 2012; Jha et al., 2012). A vicious cycle 
ensues in CKD without intervention as hallmarks of CKD progression such as oxidative 
stress, renal fibrosis, and metabolic acidosis will result in further declines in kidney 
function. Anemia, uremia, and metabolic bone disease are other characteristic 
comorbidities of CKD (KDIGO, 2013). In our ageing population there will be a much 
larger burden to the healthcare system from CKD patients due to the inevitable increases 
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we will face and due to the rise in incidence of associated risk factors (Coresh et al., 
2007).  
1.1.4.1 Diabetes 
Diabetes is reported to affect 6.8% of Canadians and this number climbs to 8.7% 
if only adults over the age of 20 are included, as risk for diabetes incidence increases with 
age (Public Health Agency of Canada, 2011). Diabetic kidney disease (DKD) is the 
leading cause of CKD and is considered a form of CKD itself by the Kidney Disease 
Quality Outcomes Initiative (KDQOI) (Żyłka et al., 2015). Hyperglycemia is necessary 
for the pathogenesis of DKD which makes patients with uncontrolled diabetes at 
increased risk to incur renal damage (Thomas, 2016). Approximately two thirds of type 2 
and one third of type 1 diabetes mellitus patients will develop DKD, while diabetes 
affects 9% of the population worldwide (Thomas, 2016; Filla and Edwards, 2016). 
Microangiopathy resulting from diabetes mellitus is the causal factor for renal damage. 
Diabetic co-morbidities such as sustained hyperglycemia, hypertension, and 
hyperlipidemia will result in microangiopathy (Żyłka et al., 2015). Diabetic 
glomerulosclerosis can also lead to hypertension (Levey and Coresh, 2012). 
1.1.4.2 Hypertension 
The prevalence of hypertension varies in CKD from 30% of stage 2 patients to 
50% in those with stage 4 CKD (Keith et al., 2004). In a retrospective study from 2012 it 
was estimated that 23% of Canadians have hypertension (Robitaille et al., 2012). This is 
a stark contrast to the 12% of Canadians at the start of the 20th century (Robitaille et al., 
2012). It is also proposed to account for 13% of all deaths globally, establishing it as the 
leading risk factor for mortality (World Health Organization, 2009; Robitaille et al., 
2012). Pathophysiologic renal function associated with hypertension originates from 
damage to the microvasculature. This can stem from high systemic blood pressure 
increasing the fluid load reaching the kidneys, as well as the velocity of blood passing 
through the renal tubules, glomerulus, and vasculature (Ravera et al., 2006; Levey and 
Coresh, 2012). Barotrauma on the renal vasculature causes mechanical stretching of 
glomerular capillaries, which induces a fibrotic repair mechanism, predisposing patients 
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to glomerular sclerosis (Ravera et al., 2006). This will further negatively impact GFR and 
exacerbate a patient’s condition. Tightly controlled blood pressure will help to reduce 
renal stress and is important for cardiovascular protection; cardiovascular disease is 
another leading cause of CKD (Ravera et al., 2006; Coresh et al., 2007). CKD is also one 
of the leading causes of hypertension and cardiovascular disease as the pathophysiology 
and treatment of the aforementioned conditions are highly interdependent (Tonelli et al., 
2016).  
1.1.4.3 Cardiovascular Disease 
 Much like diabetes and hypertension, cardiovascular disease (CVD) is a 
highly prevalent affliction globally and its incidence is rising at a rate of 8% a year 
(Tonelli et al., 2016). The highest risk populations for CVD are those from developing 
nations (Tonelli et al., 2016). CKD and ESRD patients are 5-10 fold more susceptible to 
developing CVD than healthy individuals (Tonelli et al., 2016). Cardiovascular disease is 
an umbrella term that encompasses an assortment of specific pathologic conditions such 
as coronary artery disease, atrial or ventricular arrhythmias, valvular defects, stroke, 
congestive heart failure, myocardial infarction, atherosclerosis, angina, thrombosis, 
cardiomyopathy, aneurysms, and thromboembolisms (Yusuf et al., 2001; Tonelli et al., 
2016). CVD and CKD are highly intertwined as the risk factors typically associated with 
CVD such as dyslipidemia, hypertension, and advanced age are all typically present in 
the CKD patient demographic (Segall et al., 2014). Additionally non-traditional CVD 
risk factors such as anemia, proteinuria, mineral metabolism abnormalities, volume 
overload, oxidative stress, malnutrition, and inflammation also normally accompany 
CKD (Segall et al., 2014). CKD is an independent risk factor for CVD as seen by 63% of 
these patients developing CVD (Segall et al., 2014).   
1.1.4.4 Obesity  
According to Statistics Canada in 2014, approximately 54% of Canadians self-
reported as having a body mass index (BMI) over 25 kg/m2, a 17% rise since 2003, 
displaying a sharp increase in the overweight and obese conditions over the past decade. 
Obesity is linked with many comorbidities such as cardiovascular disease, hypertension, 
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type 2 diabetes, osteoarthritis, and dyslipidemia (Tsujimoto et al., 2014; Rhee et al., 
2016). It is also known to be a leading cause of de novo CKD and ESRD (Munkhaugen et 
al., 2009; Rhee et al., 2016). Direct and indirect mechanisms have been proposed to 
account for obesity’s role in the onset of CKD. Indirect pathways include risk factors 
associated with obesity that have correlations with CKD development, such as 
hypertension, diabetes, and atherosclerosis (Stenvinkel et al., 2013; Rhee et al., 2016). 
Obesity linked mechanisms that are proposed to directly cause CKD include alterations in 
renal blood flow, inflammation, as well as growth factor and adipokine production 
(Wickman and Kramer, 2013; Stenvinkel et al., 2013; Rhee et al., 2016). A major 
proposed pathway follows that obesity can cause renal mesangial expansion resulting in 
increased metabolic demand from the kidneys, further leading to glomerular 
hyperfiltration, hypertrophy, and hypertension (Wickman and Kramer, 2013; Rhee et al., 
2016). Increased glomerular load over a prolonged period results in glomerulosclerosis 
and proteinuria (Wickman and Kramer, 2013; Rhee et al., 2016). Obesity is also linked to 
the progression of CKD to ESRD, as increasing BMI correlates with progression to 
ESRD (Ahmadi et al., 2015; Rhee et al., 2016). Paradoxically in a meta-analysis from 
2015 a relationship between survival of late stage non-dialysis dependent CKD patients 
and BMI showed that overweight and class I obesity patients had lower mortality than 
those who were underweight (Ahmadi et al., 2015; Rhee et al., 2016). A similar 
relationship was found in patients on hemodialysis as patients with a BMI between 40-45 
kg/m2 were shown to have a 31% lower mortality rate than patients with a BMI range 
from 25-27.5 kg/m2 (Doshi et al., 2015; Rhee et al., 2016).  
1.2 Uremia 
Uremia is a term that encompasses the extensive abnormalities attributed to 
declining or the complete loss of renal function (Depner, 2001). As literature on the topic 
evolves some of the more specific symptoms previously grouped with uremia such as 
anemia and hypertension, have been delineated as independent conditions (Meyer and 
Hostetter, 2007). The current perspective on the etiology of uremia follows that decreased 
kidney function results in a state of intoxication due to accumulation of organic waste 
products that would normally be excreted in the urine (Depner, 2001; Meyer and 
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Hostetter, 2007). Early symptoms of uremia such as fatigue are difficult to allocate to a 
specific origin and often lead to the ailment going undetected (Meyer and Hostetter, 
2007). Advanced stage CKD displays more characteristic uremic syndrome that can 
specifically demarcate the condition (Depner, 2001). Anorexia, pruritus, serositis, 
hemorrhage, reduced attention span, lethargy, fluid retention, edema, as well as 
biochemical and hormonal irregularities are all signs of advanced uremic syndrome 
(Depner, 2001). The advent of dialysis has mitigated complications associated with 
uremia as it makes renal replacement more accessible, dialysis is currently the only way 
to minimize the effects of uremia and its associated symptoms (Meyer and Hostetter, 
2007). Prophylactic measures can hinder the progression of CKD to eventual ESRD and 
thereby reduce the effect of uremic syndrome as renal function is preserved (Meyer and 
Hostetter, 2007). There is currently no artificial apparatus that can compare to an actual 
functioning kidney and a result of this short-coming is a condition known as residual 
syndrome, which is experienced by dialysis patients (Depner, 2001). Large molecular 
weight solutes as well as smaller protein-bound molecules are poorly dialyzed, and in 
conjunction with tissue calcification and hormone imbalance, they are considered the 
putative causes for residual syndrome (Depner, 2001). These solutes are called uremic 
toxins and have come into prominence in the nephrology field recently. Uremic serum 
has been shown to impair the integrity of the tight junctions in the intestinal epithelium, 
allowing increased passage of these uremic toxins into the internal environment (Vaziri et 
al., 2012). The ensuing subsections will address the hypothesized mechanisms for their 
abundance as well as classifications of the commonly studied toxins.  
1.2.1 Intestinal Microbiome 
The microbial population of the gut is enormous, with approximately 1014 bacteria 
from 500-1000 different species taking up residence within it (Backhed et al., 2004; 
Ramezani et al., 2016). Physiologically the microbes in our gut are responsible for 
necessary metabolic actions that our bodies are not equipped to fulfill, including the 
synthesis of certain vitamins and amino acids, as well as the catabolism of certain 
complex polysaccharides and bile acids (Hill, 1997; Hylemon and Harder, 1998; Hooper 
et al., 2002; Ramezani et al., 2016). The gut appears to be a dynamic biome in which its 
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microbial resident demographic will change based on host diet as certain taxonomies are 
better adapted to metabolize different foods, which gives credence to the theory that 
bacterial colonies adapt to host needs (Ramezani et al., 2016).  
1.2.1.1 Dysbiosis in CKD 
The uremic condition leads to high levels of undigested proteins in the distal 
intestine, which promotes the growth of proteolytic bacteria (Sorensen, 1965; Ramezani 
et al., 2016). This leads to a pathologic overhaul in microbiome composition and 
metabolic potential which is termed dysbiosis (Ramezani et al., 2016). Patients suffering 
from ESRD are shown to have significant increases in relative abundance of 190 bacterial 
operational taxonomic units as compared to healthy controls (Vaziri, Wong, et al., 2013). 
It has also been shown that rats post-subtotal nephrectomy have a significant decline in 
overall species richness for gut microbiota (Vaziri, Wong, et al., 2013). Overall microbial 
diversity is shown to decrease in CKD, however there are bacterial families that are 
shown to excel in the disease environment and actually increase their diversity, such as 
the Pseudomonadaceae, which exemplifies the notion that the enteric milieu imposes 
selection pressures upon its occupants (Vaziri, Wong, et al., 2013). By in large aerobic 
bacteria outcompete anaerobic counterparts in CKD due to decreased gut motility which 
is secondary to decreased myoelectrical activity in enterocytes (Strid et al., 2003). 
Changes in excretion routes for both uric acid and oxalate combined with enteric influx 
of urea, long term administration of phosphate binding agents, strict dietary restrictions, 
and frequent use of antibiotics are the putative explanations for the observed differences 
in microbial flora in the CKD populous (Vaziri, Wong, et al., 2013).  
1.2.2 Uremic Toxins 
Metabolic differences in CKD can be attributed to changes in the gut microbiome 
and higher levels of undigested protein reaching the colon, which can result in higher 
levels of protein fermentation (SA Gibson et al., 1989; Ramezani et al., 2016). Toxic 
molecules derived from dietary proteins can accumulate due to the lack of renal clearance 
and the invigorated production of ammonia, indoles, amines, thiols, and phenols 
secondary to enteric dysbiosis (SA Gibson et al., 1989). There are more than 115 
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identified uremic toxins to date and they can been subdivided into free water-soluble low 
molecular weight molecules, middle molecules, and protein-bound molecules using a 
classification system that accounts for size and proteins binding properties (Vanholder et 
al., 2008; Duranton et al., 2012). Advances in techniques in the field such as untargeted 
metabolomics, have greatly aided investigators in the identification process and provide 
information on which toxins differ in concentration between control and CKD subjects 
(Velenosi et al., 2016).  
The free water-soluble low molecular weight toxins (<500Da) comprise 46% of 
the currently identified uremic toxins (Duranton et al., 2012). These solutes are typically 
easily removed by dialysis due to their water solubility and minimal protein binding. 
Notable members are urea, creatinine, guanidine metabolites (e.g. guanidinosuccinic 
acid), and asymmetric dimethylarginine (Lisowska-Myjak, 2014). Reactive carbonyl 
species such as alkanals, alkenals, and 4-OH-alkenals that arise due to oxidative 
conditions in CKD are also included in this class of uremic toxin (Alhamdani et al., 
2006). Another water-soluble uremic toxin coming into prominence is trimethylamine N-
oxide (TMAO), as it has been shown to have proatherogenic properties (Koeth et al., 
2013). Choline and L-carnitine are the precursors for TMAO, while their origins are 
derived from red meat and eggs in the diet (Moraes et al., 2015). TMAO is elevated in 
ESRD patients, although hemodialysis is able to clear it  to a degree, it does not restore it 
to levels seen in controls (Bain et al., 2006; JY Choi et al., 2011). 
Middle molecules account for 28% of currently identified uremic toxins and are 
classified by a molecular weight in excess of 500 Da. (Duranton et al., 2012; Lisowska-
Myjak, 2014). Solutes over 60kDa are not typically filtered by the glomerulus and 
therefore are not considered uremic toxins (Duranton et al., 2012). The main constituents 
of this class are cytokines including IL-6, IL-8, IL-10, TNF-𝛼, and β2-microglobulin 
(Duranton et al., 2012). Other members of note are adiponectin, leptin, ghrelin, 
endothelin, and cholecystokinin (Lisowska-Myjak, 2014). These solutes are efficiently 
removed by dialysis modalities that incorporate high-flux membranes (Winchester and 
Audia, 2006). Studies have reported correlations between lower levels of middle 
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molecules in dialysis patients and a decreased risk for all-cause and cardiovascular 
mortality (Hornberger et al., 1992; Eknoyan et al., 2002).  
1.2.2.1 Protein-Bound and Gut-Derived Uremic Toxins 
Protein-bound solutes account for 25% of currently identified uremic toxins, they 
are typically smaller molecular weight (<500Da) and many are gut-derived (Duranton et 
al., 2012). The protein-bound molecules are of particular interest to this study as they are 
poorly cleared by dialysis. Once they have breached the intestinal barrier, metabolites can 
be further metabolized or altered at sites such as the liver. A well characterized protein-
bound uremic toxin is indoxyl sulfate (93% bound to albumin in circulation) due to its 
putative effects on the cardiovascular system and drug metabolism (Niwa, 2013; Devine 
et al., 2014). Starting as tryptophan (derived from dietary protein) and upon exposure to 
intestinal bacteria containing tryptophanase, it is metabolized to indole (Niwa, 2013; 
Ramezani et al., 2016). Indole is then able to cross the intestinal barrier and enter portal 
circulation, which allows for hepatic uptake and subsequent hydroxylation followed by 
sulfation in the liver to indoxyl sulfate (Banoglu et al., 2001; Meijers et al., 2009; Niwa, 
2013). Despite high protein binding, indoxyl sulfate is extensively cleared by renal 
tubular secretion in the proximal tubule cells of the kidney. In CKD, indoxyl sulfate 
accumulates and manifests nephrotoxic properties primarily via induction of reactive 
oxygen species production in both renal tubular cells and glomerular mesangial cells 
(Niwa, 2013). It has also been shown to have a pathophysiological role on various 
functions in the endothelium, heart, smooth muscle cells, intestinal cells, leukocytes, 
adipocytes, and hepatic metabolism and transport (Shibata et al., 2000; Sun et al., 2006; 
Vanholder et al., 2014). Many studies have investigated its contribution to cardiovascular 
disease (Niwa, 2013; Inami et al., 2014). 
The metabolic pathways of both p-cresyl sulfate and hippuric acid are also well 
understood as they originate from the hydrophobic amino acids tyrosine and 
phenylalanine respectively. P-cresyl sulfate binds to albumin at the same site indoxyl 
sulfate does with 90% of total p-cresyl sulfate being protein-bound (De Smet et al., 1998; 
Meijers et al., 2009). Systemic detrimental effects related to p-cresyl sulfate have been 
shown in apidocytes, renal tubular cells, and leukocytes (Vanholder et al., 2014). 
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Elevated serum p-cresyl sulfate has also been shown to associate with higher all-cause 
mortality in CKD patients on hemodialysis (Wu et al., 2012). Another prominent uremic 
toxin is 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF), and it is also 
highly protein-bound as 99% exists bound to albumin (Meijers et al., 2008). CMPF has 
been implicated in a plethora of pathophysiological mechanisms including thyroid 
dysfunction, inhibition of hepatic metabolism and mitochondrial respiration, and the 
production of ROS in endothelial cells (Niwa, 2012). 
1.3 Removal of Gut-Derived Uremic Toxins 
Gut-derived uremic toxins are typically protein bound, adding another layer of 
difficulty in regards to their removal as they cannot be efficiently filtered by the 
glomerulus. The main physiological pathway for their excretion is through tubular 
secretion, into the urine. Tubular secretion involves transporter proteins such as OAT1, 
OAT3, BCRP, and MRP4 (Poesen et al., 2013). The major reasons for the accumulation 
of gut-derived uremic toxins appears to be the loss of renal function, the inability of 
dialysis to clear the small molecules, saturation of tubular transporters, and colonic 
dysbiosis resulting in increased production of these solutes. There are several proposed 
mechanisms to reverse the pathologic retention of these molecules (Vanholder et al., 
2016). Dietary restrictions are the most accessible and recommendations are in place to 
lower the intake of protein to reduce the accumulation of nitrogenous waste products 
associated with azotemia (Ritz et al., 1978). A study in rats that had undergone subtotal 
nephrectomy to reduce GFR were administered isocaloric diets that differed on the main 
caloric constituent, attempted to elucidate any benefit of reduced dietary protein in CKD. 
The animals receiving high protein diets had a markedly shorter lifespan than those on 
high fat or high carbohydrate diets, exemplifying the benefit of protein restriction in CKD 
(Ritz et al., 1978). Protein restriction ameliorates aspects of the uremic syndrome but it 
can be difficult to balance proper nutrition with optimal protein intake as uremic patients 
suffer from a loss of appetite and a particular aversion to protein-rich foods, making it 
difficult to reach daily protein intake goals, potentially resulting in malnutrition (Sirich, 
2014). This makes it difficult for CKD patients to adhere to diets tailored to control 
protein intake.  
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Another option is to increase dietary fiber consumption as it decreases colonic 
transit time, therefore reducing the period of time the gut bacteria has to metabolize food 
and create protein-derived solutes (Sirich, 2014). Natural fiber is resistant to mammalian 
digestion and typically contains components of plant cell walls in high proportions. 
Synthetic fibers also exist and they have beneficial effects on gastrointestinal health, 
largely pertaining to gut motility (Sirich, 2014). High fiber foods may also provide more 
energy for the colonic bacteria which could facilitate an increase in bacterial protein 
synthesis and a decrease in uremic solutes as it consumes the available nitrogenous bases 
(Sirich, 2014). In humans with CKD treated with fiber for 5 weeks there was a 23% 
reduction in plasma urea in addition to a 50% increase in nitrogen excretion in the feces 
(Younes et al., 2006). The effect of fiber on other uremic toxins was seen in hemodialysis 
patients randomized to fiber supplements or corn starch; 27% and 24% reductions in 
indoxyl sulfate and p-cresyl sulfate respectively were observed in the patients who 
received the fiber supplementation (Sirich et al., 2014).  
The use of probiotics and prebiotics has become a hot topic amid the notion of 
dietary alterations to reduce uremic toxin accumulation (Koppe et al., 2015). Probiotics 
are a preparation that contains viable microorganisms in sufficient number to alter the 
host microflora and to confer beneficial effects to the host (Schrezenmeir and de Vrese, 
2001). Anaerobic bacteria such as Lactobacillus and Bifidobacterium are common in 
probiotic cultures (Guida et al., 2014). Prebiotics are non-digestible compounds that can 
support probiotic bacterial fermentation, providing a competitive advantage over 
pathologic bacteria in energy availability (GR Gibson et al., 2010). A convenient 
preparation containing both pre- and probiotics is called a synbiotic (Guida et al., 2014). 
Work by Guida et al in 2014 showed that synbiotics can reduce plasma p-cresol 
concentrations in CKD patients. A randomized clinical trial from 2016 that administered 
synbiotics to CKD patients showed a non-significant reduction of serum indoxyl sulfate; 
however, p-cresyl sulfate concentrations were significantly lowered and there was also 
increased growth of beneficial bacteria combined with lowered pathologic microbiota 
(Rossi et al., 2016).  
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1.3.1 AST-120 
There is one other well-documented method for the removal of gut-derived 
uremic toxins. It involves the administration of AST-120, a spherical oral adsorbent 
comprised of porous microcrystalline carbon derived from petroleum pitch (Kanai et al., 
1986; Niwa et al., 1991). Each particle is 0.2-0.4mm in diameter and is insoluble in both 
water and organic solvents (Niwa et al., 1991). AST-120 functions much like traditional 
activated charcoal with key differences being its fluidity in the GI tract due to its 
spherical shape, and its molecular weight selective properties (Niwa et al., 1991). It 
targets molecules between 100-10000 daltons, therefore limiting its effects on digestive 
enzymes. It has close to 10 fold lower affinity for endogenous enzymes such as 
chymotrypsin, amylase, lipase, and aminopeptidase compared to activated charcoal on a 
mg per g ratio of enzyme to drug (Kanai et al., 1986). AST-120 has shown an ability to 
lower circulating levels of uremic toxins while having only mild side effects. The only 
reported side effects are constipation, nausea, and diarrhea; however these ADRs occur at 
a similar rate in placebo treated patients (Schulman et al., 2014).  
Activated charcoal has shown efficacy for alleviating pruritus in hemodialysis 
patients; however, AST-120 has been shown to be efficacious in this regard as well, and 
may be a less detrimental alternative (Niwa et al., 1991). CKD patients are on many oral 
medications and there have been concerns over AST-120 interfering with their 
absorption. Oral medications tested for this retained their desired therapeutic effect if 
they were consumed 30 minutes prior to AST-120 administration (Niwa et al., 1991). 
Since AST-120 displays a high tolerability allowing for sustained administration over a 
long period of time, Japan approved its use to slow the progression of CKD in 1991. 
Studies showed a delay in the initiation of hemodialysis and to relief of uremic symptoms 
(Niwa et al., 1991; Schulman et al., 2014). It was subsequently approved in both Korea 
(2005), the Philippines (2010) and is currently going through phase III trials in North 
America, Europe, and Latin America (Schulman et al., 2014). Efforts to use AST-120 in 
Europe and North America culminated in the Evaluating Prevention of Progression in 
CKD trials (EPPIC-1 & 2), which were conducted simultaneously and compiled 5840 
patients across 13 countries (Schulman et al., 2015). The EPPIC trials failed to indicate a 
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beneficial effect for AST-120 in the progression of CKD as determined by the triple 
composite endpoint including either the onset of dialysis, kidney transplantation, or 
doubling of serum creatinine (Schulman et al., 2015). There were many limitations to this 
study however and it contradicted multiple clinical trials completed in Japan (Shoji et al., 
2007; Hatakeyama et al., 2012).  
 Many studies have evaluated the reduction of serum indoxyl sulfate by AST-120, 
including a large clinical trial that showed a 40% reduction in moderate and severe CKD 
patients (Schulman et al., 2006). A metabolomics study in rats with adenine-induced 
CKD displays differences in prevalence for many molecules across distinctive biological 
matrices between control, CKD, and the aforementioned groups treated with AST-120 
(Velenosi et al., 2016). AST-120 was able to significantly reduce 24 of 26 plasma 
metabolites that were higher in CKD than control, while lowering 50% of CKD specific 
metabolites in both liver and heart tissue, which had 107 and 56 metabolites identified 
respectively (Velenosi et al., 2016). There were 8 common metabolites significantly 
higher in CKD than control for plasma, liver, heart, and kidney tissues. (Velenosi et al., 
2016). P-cresyl sulfate, indoxyl sulfate, hippurric acid, P-cresyl glucuronide and phenyl 
sulfate are all among those 8 metabolites and unsurprisingly they were all reduced by 
AST-120 as they have been previously identified as gut-derived toxins (Velenosi et al., 
2016). The same rat model was employed by Vaziri et al in 2013 to show a restoration of 
the intestinal epithelium tight-junction proteins in rats that were provided AST-120. 
Improvement of oxidative stress markers has also been associated with AST-120 as high 
ROS are often attributed to uremic toxin accumulation in CKD patients (Niwa, 2013; 
Vaziri, Yuan, et al., 2013; Yamamoto et al., 2015). AST-120 has been shown to lower 
arterial pressure and serum malondialdehyde, a plasma-lipid peroxidation product in rats 
with CKD (Vaziri, Yuan, et al., 2013). Yamamoto et al in 2015 showed a significant 
reduction of oxidized albumin levels in hemodialysis patients that received AST-120. 
Finally, as there are many studies on the effects of indoxyl sulfate and uremic toxins on 
vascular disease, multiple groups have looked at AST-120 and whether it can attenuate or 
reverse these effects (Niwa, 2013). It has been shown to reduce carotid artery intima-
media thickness, arterial stiffness, and delayed the progression of monocyte adhesion in 
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the endothelial cells which is characteristic of the uremic condition (Nakamura et al., 
2004; Inami et al., 2014). 
1.4 Drug Metabolism and Disposition 
The typical CKD patient is prescribed 12 different drugs concurrently in order to 
manage an average of 6 comorbidities associated with the underlying disease (Manley et 
al., 2005). Extensive knowledge of drug pharmacokinetics is therefore of utmost 
importance. In order for these drugs to mediate their prescribed benefits they need to 
reach an appropriate concentration at their site of action in the body. A harmonious 
system of absorption, distribution, metabolism, and elimination govern the plasma and 
tissue concentration of drugs. To further illustrate this process, the pathways of an orally 
administered drug will be explained.  
Upon ingestion of a typical orally administrated drug, it will pass through the 
gastrointestinal tract until it reaches the small intestine. If the drug is a weak acid then 
there may be some absorption in the stomach due to pH partitioning, however the 
majority of drug absorption will occur further down the GI tract. Reasoning for this is 
although rugae in the stomach increase gastric surface area, the villi and microvilli of the 
small intestines provide a substantially greater surface area for absorption, 3800 fold 
larger by some estimates (DeSesso and Jacobson, 2001). Uptake transporters can remove 
substrates from the intestinal lumen and translocate them across the apical intestinal 
epithelium. At this point enteric metabolism can occur and the drug will be left with 2 
options; the first being subsequently effluxed by transporters back into the intestinal 
lumen for fecal excretion if it does not undergo repeated uptake, metabolism, and efflux 
(Nolin et al., 2008). The drug can also follow a path into the portal circulation by 
crossing the enteric basolateral membrane via efflux transport or passive diffusion (Nolin 
et al., 2008; Yeung et al., 2014). Exposure to first pass metabolism will occur through 
this route as passive diffusion or uptake transporters on the sinusoidal membrane of 
hepatocytes can internalize xenobiotics. Once in the liver drugs can be metabolized, then 
effluxed across the canalicular membrane and into the bile for fecal excretion. 
Alternatively, drugs may also move back across the basolateral membrane and into the 
hepatic vein and then into systemic circulation (Nolin et al., 2008). Metabolites that are 
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undergoing biliary elimination may be reabsorbed in the intestines through enterohepatic 
recirculation (Nolin et al., 2008). This typically requires the restoration of the parent drug 
by removal of phase II metabolic conjugations by bacterial enzymes in the intestinal 
lumen. 
Drugs and metabolites that reach systemic circulation can be eliminated by renal 
excretion by filtration at the glomerulus or by transporter mediated tubular secretion. In 
combination with biliary excretion, these comprise the major physiological processes to 
remove drugs and toxins from the body. Drug dosing needs to account for renal and 
hepatic clearance rates in order to ensure optimal plasma concentrations while avoiding 
toxicity. There are clearly many factors dictating the pharmacokinetics of a drug. 
Metabolism and drug transport will be further expanded upon in the ensuing sections.  
1.4.1 Metabolism 
The metabolic processes in the body are defined by phase I and phase II reactions. 
These reactions occur predominantly in the liver, however the kidneys, intestine, and 
lungs are known to have metabolic activity as well. The primary focus of phase I 
metabolism is to unmask polar groups on lipophilic drugs through reduction, oxidation 
and hydrolysis reactions, occurring on the smooth endoplasmic reticulum of the cell. This 
results in deactivation or activation of a drug, depending on its properties (pro-drug or 
not). The majority of phase I metabolism is carried out by the Cytochrome P450 
superfamily (CYP). Phase II consists of the conjugation of polar groups to lipophilic 
compounds or metabolites from phase I and is completed by sulfotransferases, 
glutathione-S-transferases, N-acetyltransferases, thiopurine methyltransferase, and UDP-
glucuronosyltransferases. Phase II generally follows phase I metabolism, however it may 
also be solely responsible for the metabolism of certain drugs. It is estimated that 73% of 
currently marketed drugs require metabolism for clearance (Wienkers and Heath, 2005). 
1.4.1.1 Cytochrome P450 Superfamily 
Cytochrome P450 enzymes are heme-containing mono-oxygenases that are 
ubiquitously expressed across phylogenies and are localized to the smooth endoplasmic 
reticulum of cells. There are currently 57 known human CYPs, with approximately 35 
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isoenzymes showing clinical relevance (Martignoni, Groothuis, and de Kanter, 2006a; 
Guengerich, 2008). CYPs are divided into 12 different families demarcated by a number, 
a letter, and then another number. The first number denotes the family and signifies over 
40% primary structural sequence similarity, the letter then divides them into subfamilies 
which are >55% identical in terms of primary structure (Martignoni, Groothuis, and de 
Kanter, 2006a; Guengerich, 2008). The final number in CYP nomenclature distinguishes 
the individual enzyme (Martignoni, Groothuis, and de Kanter, 2006a). CYP enzymes 
account for 75% of xenobiotic metabolism and of that, 95% is attributable to 5 enzymes 
(Guengerich, 2008; Schwab and Zanger, 2013). Human CYP3A4 accounts for 30% of 
CYP drug metabolism while 1A2, 2A6, 2B6, 2C8, 2C9, 2C11, 2D6, and 2E1 play large 
roles as well (Guengerich, 2008; Schwab and Zanger, 2013). The CYP3A family plays 
the largest role in drug metabolism and therefore is the best described in the literature for 
pharmacogenomic and disease-state studies.  
Since the majority of marketed drugs are metabolized primarily by a small set of 
enzymes there is the potential for serious drug-drug as well as food-drug interactions if a 
target enzyme is inhibited, induced, or suffers a loss of activity. The importance of this is 
showcased in the classic example of felodipine bioavailability increasing with concurrent 
grapefruit juice consumption with the mechanism of action being enteric CYP3A4 
inhibition (Bailey et al., 1998). A single 250mL serving of grapefruit juice was able to 
increase felodipine plasma area under the curve by 267% (Bailey et al., 1998). CYPs are 
also highly polymorphic, which requires another layer of caution when dosing patients 
with substrates. The CYP2C9 and warfarin example is very well defined in the literature 
and shows single nucleotide polymorphisms (SNPs) occur in 34% of patients for the 2C9 
gene (Freeman et al., 2000). In addition to wild type CYP2C9*1 there are 2C9*2 and 
2C9*3 SNPs (Freeman et al., 2000). The *2 and *3 SNPs result in a loss of activity in 
CYP2C9, which will result in extensive anti-coagulant toxicity and hemorrhage if dose 
adjustments are not made (Freeman et al., 2000).  
1.4.1.2 CYP2B Subfamily 
The CYP2B family was historically thought to account for very little of total CYP 
metabolism. Recent studies however estimate that CYP2B6 and 2B7 are responsible for 
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the metabolism of 25-30% of drugs, neutraceuticals, and herbal medicines on the market, 
and that 2B6 alone metabolizes 7.2% of clinically used drugs (Xie and Evans, 2001; 
Schwab and Zanger, 2013). CYP2B7 is expressed in the lung so the majority of attention 
is directed towards CYP2B6 which is expressed in the liver as well as some extrahepatic 
tissue (Martignoni, Groothuis, and de Kanter, 2006b). The expression of CYP2B6 is 
highly variable but using sensitive immunochemical detection it was shown to account 
for 6% of total CYP content in the liver (Stresser and Kupfer, 1999). There is very high 
interindividual variability reported for CYP2B6 as 25-250 fold differences have been 
reported; ethnicity specific differences have arisen as well, as only 30% of Japanese liver 
samples displayed detectable CYP2B6 expression as opposed to 85% in Caucasians 
(Code et al., 1997; Martignoni, Groothuis, and de Kanter, 2006b). Human CYP2B6 
shares 75-76% sequence homology with rat CYP2B1 and 2B2 (Ekins and Wrighton, 
1999). Rat CYP2B1 and 2B2 are isoenzymes that are difficult to differentiate as they 
share 97% primary structural identity and high substrate overlap (Waxman, 1988). The 
only notable difference between the two is CYP2B1 is considered the more catalytically 
active of the pair (Waxman, 1988; Pekthong et al., 2012).  
1.4.1.3 Bupropion Metabolism 
The metabolism of a CYP2B selective marker for activity highlights the 
difference between 2B1 and 2B2 (Pekthong et al., 2012). Bupropion is both a 
norepinephrine and dopamine reuptake inhibitor that was originally prescribed as an 
antidepressant but has been shown to be efficacious as a smoking cessation agent (Holm 
and Spencer, 2000; Stahl et al., 2004). CYP hydroxylation of this drug results in the 
active metabolite hydroxybupropion (OH-BUP), and this is the predominant pathway for 
bupropion clearance; 75% of OH-BUP generation is attributable to CYP2B1, while 
CYP2E1 and 2C11 account for 10.9% and 8.7% respectively (Pekthong et al., 2012). In 
humans CYP2B6 is also the primary metabolic enzyme responsible for bupropion’s 
conversion to OH-BUP and bupropion has been validated as an appropriate marker for 
2B6 function as it accounts for 71% of OH-BUP formation (Hesse et al., 2000; Faucette 
et al., 2000). Multiple studies have reported alterations in BUP pharmacokinetics in renal 
impairment. A clinical study from 2007 showed a 66% reduction in the conversion of 
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BUP to OH-BUP in patients with CKD compared to healthy controls (Turpeinen et al., 
2007). Another study showed increased plasma and brain concentrations of BUP and 
OH-BUP in guinea pigs that had renal impairment induced by uranyl nitrate (DeVane et 
al., 1986). 
1.4.2 Transport 
Drugs that are unable to cross the lipid bilayer of the cell require facilitation in the 
form of transport proteins in order to cross biological membranes. Drug transporters are 
integral in the absorption and excretion of xenobiotics, as well as determining the degree 
of penetrance into tissue (Ho and Kim, 2005). They are large, membrane bound proteins 
that are highly expressed at sites of drug absorption and secretion including the liver, 
kidney, and intestines (DeGorter et al., 2012). They are also present at sites where drug 
accumulation would be unfavourable such as the testes, placenta, and blood-brain-barrier 
(DeGorter et al., 2012). Over 400 transporters have been characterized in the human 
genome from the ATP-Binding Cassette (ABC) and Solute Carrier (SLC) superfamilies 
(Giacomini et al., 2010). These families show large interindividual differences in 
expression and function largely due to genetics, disease, lifestyle, and xenobiotic 
interactions (Ho and Kim, 2005; Giacomini et al., 2010). They can also be classified as 
uptake or efflux transporters.  
1.4.2.1 SLC Superfamily 
Members of the SLC family of transporters have >20% sequence homology and 
can be subdivided into Organic Cation Transporters (OCTs), Organic Anion Transporters 
(OATs), Organic Anion Transporting Polypeptides (OATPs), and the Sodium-
Taurochlorate Co-transporting Polypeptide (NTCP) (DeGorter et al., 2012). They are 
uptake transporters that are largely localized on the sinusoidal membrane of hepatocytes, 
permitting the movement of drugs from the blood into the liver. They also play a large 
role in uptake of substrates from the intestinal lumen into enterocytes. The SLC 
transporters function in a variety of ways with the most common being facilitative 
diffusion and secondary active transport in the form of ion coupling or ion exchange 
(DeGorter et al., 2012).  
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1.4.2.1.1 Organic Anion Transporting Polypeptide Superfamily 
OATPs are very well characterized structurally and functionally, they are 
speculated to contain 12 transmembrane domains and drive transport in a sodium 
independent fashion (Hagenbuch and Meier, 2003). They harbour several highly 
conserved N-glycosylsation domains which are imperative for proper function and 
membrane localization, which is dependent on the degree of glycosylation (Hagenbuch 
and Gui, 2008). The SLCO genes code for the respective OATP protein produced. In 
2004 Hagenbuch and Meier described OATP proteins with >40% sequence homology 
being within the same family (OATP1-6), while >60% amino acid identity will put them 
in the same subfamily (OATP1A/B/C etc…). To date 52 members of the superfamily 
have been discovered (36 in humans), and they are organized into 6 families with 13 
subfamilies (Hagenbuch and Meier, 2004).  These transporters have a wide substrate 
specificity but some general criterion appear to be transport of amphipathic molecules, 
molecular weight >450Da, with high degrees of protein binding under physiological 
conditions (Hagenbuch and Meier, 2003). This encompasses endogenous molecules such 
as bile acids, thyroid hormones, as well as glucuronidated and sulfonated compounds 
alike (Hagenbuch and Meier, 2004). Of interest to this project, OATPs also have affinity 
for many xenobiotics, including the statin class of therapeutic agents and the anti-
histamine fexofenadine (Hagenbuch and Meier, 2003; Ho et al., 2006; Gradhand et al., 
2013). It is hypothesized that these proteins can govern bidirectional transport, depending 
on concentration gradients of substrates, however they are studied in large part for their 
role as uptake transporters (Hagenbuch and Meier, 2004). OATPs function through 
organic cation exchange while using bicarbonate, reduced glutathione, and glutathione 
conjugates as counter-ions in this process (Hagenbuch and Gui, 2008; Hagenbuch and 
Stieger, 2013).  
OATPs are ubiquitously expressed in the body although some isoforms have 
tissue specific expression patterns (Hagenbuch and Stieger, 2013). Isoforms in locations 
such as the liver and intestine are of particular importance to this study. The role of 
OATPs in drug disposition is elegantly demonstrated with the diminished bioavailability 
of the transporter probe fexofenadine, when administered in the presence of a potential 
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OATP inhibitor. A study from 2005 showed a 42% reduction in the oral bioavailability 
fexofenadine, potentially due to the inhibition of enteric uptake transporters by grapefruit 
juice, displaying the importance of OATPs in drug pharmacokinetics (Dresser et al., 
2005). OATP1B1 and 1B3 (previously OATP-C and OATP8 respectively) are two 
proteins expressed exclusively on the sinusoidal membrane of the liver and play a large 
role in drug clearance (Hagenbuch and Meier, 2004). They share 80% sequence identity, 
are both from the OATP1B subfamily, and are of similar size, 691 and 702 amino acids 
long for 1B1 and 1B3 respectively (Hagenbuch and Gui, 2008). Due to their crucial role 
in drug disposition, there is a high potential for drug-drug interactions and adverse drug 
reactions (ADR) as they have affinity for such a broad spectrum of substrates 
(Hagenbuch and Gui, 2008). 
Mutations and polymorphisms in OATPs can lead to altered function and 
contribute to pathological disorders (Tirona et al., 2001). There is an assortment of 
mendelian diseases associated with the SLC family with the severity varying from benign 
to life threatening (Lin et al., 2015). A mutation in the SLCO1B1 and 1B3 genes 
resulting in a loss of function of the respective OATP proteins has been shown to lead to 
rotor syndrome in humans (van de Steeg et al., 2012). It is characterized by high levels of 
conjugated and unconjugated hyperbilirubinemia along with coproporphyrinuria and 
altered bromosulfophthalein clearance (van de Steeg et al., 2012). Mutations in both the 
1B1 and 1B3 genes are required to see the phenotype due to the high substrate overlap 
between the transporters (Lin et al., 2015).  
1.4.2.2 ABC Superfamily 
The ABC superfamily is responsible for efflux transport and requires energy from 
ATP hydrolysis to power the movement of its substrates against concentration gradients, 
thus a defining feature of these proteins is a highly conserved ATP-Binding motif 
(DeGorter et al., 2012). Constituents of this family include P-glycoprotein (P-gp/ 
MDR1/ABCB1), breast cancer resistance protein (BCRP/ABCG2), multidrug resistance-
associated protein (MRP/ABCC), and the bile salt export pump (BSEP/ABCB11) 
(DeGorter et al., 2012). These proteins play an important role in conferring drug 
resistance as they are in large part localized on the canalicular membrane of hepatocytes 
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and the apical membrane of enterocytes, hepatocytes, renal proximal tubule cells, and the 
blood-brain-barrier endothelium (DeGorter et al., 2012). The tissue distribution of P-gp 
in particular shows the importance of efflux transport in detoxification pathways as it is 
able to move compounds into the bile, feces, urine, and away from the brain (Nolin, 
2008). Other canalicular transporters of interest are BSEP and BCRP as they, along with 
P-gp, have broad substrate specificities and allow for the process known as enterohepatic 
recirculation by pumping substrates into the bile ducts (Nolin et al., 2008; Yeung et al., 
2014).  
1.4.3 Nuclear Regulation 
The expression of different metabolic and transporter proteins can have a large 
effect on the therapeutic or toxicological effect of a drug. Nuclear receptors are a 
superfamily comprised of genes that produce transcription factors, which modulate gene 
expression. There are over 70 members of this superfamily, all share similar sequence 
identity and contain 4 similar modalities, the modulator domain, DNA-binding domain 
(DBD), hinge region, and ligand binding domain (LBD) (Giguère, 1999; Wang and 
LeCluyse, 2003). The modulator domain is located at the 5’ amino terminus and is 
considered the most variable of the modalities (Giguère, 1999). It contains an activation 
function domain-1 that allows for ligand-independent activation so long as other nuclear 
receptors or coactivators are present (Giguère, 1999; Urquhart et al., 2007). The DBD is 
the most highly conserved domain but since receptors can bind DNA as monomers, 
homodimers, or heterodimers there is inevitably some variation between individual 
receptors (Giguère, 1999). This region is aptly named as it is responsible for interaction 
of the receptor with target DNA sequences (Giguère, 1999). The hinge region gives the 
receptor flexibility between the DBD and LBD, allowing for dimerization and may pose 
as a docking site for repressor elements (Giguère, 1999). The LBD principally moderates 
ligand interactions but extends its purpose to mediate dimerization, nuclear localization, 
and interactions with heat shock proteins (Giguère, 1999). It also facilitates ligand-
dependent-transactivation through activation function domain-2 (Giguère, 1999).  
There are two perceived mechanisms of action for nuclear receptors, with the 
traditional one being that an inactive cytoplasmic receptor will subsequently translocate 
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to the nucleus once a ligand has bound to it. Many nuclear receptors heterodimerize with 
the retinoid X receptor (RXR) upon entering the nucleus, facilitating interactions with the 
promoter or enhancer regions of the target gene (Urquhart et al., 2007). Other nuclear 
receptors are constitutively active and do not require a ligand to facilitate DNA binding 
(Giguère, 1999). In the latter model, ligand binding may actually dissociate receptors 
from the DNA.  
1.4.3.1 Orphan Nuclear Receptors 
A sub-family known as orphan nuclear receptors accounts for 60% of the nuclear 
receptor superfamily (Giguère, 1999; Wang and LeCluyse, 2003). The orphan 
nomenclature originated when the first member was discovered in 1988 and all 
previously identified receptors had a known physiological function with an associated 
hormone or ligand, these had yet to be established and were instead assigned the 
preceding title of orphan to acknowledge this (Giguère et al., 1988). Members of this 
family govern the transcriptional expression of prominent metabolic enzymes and 
transport proteins (Wang and LeCluyse, 2003; Tirona and Kim, 2005). Exogenous and 
endogenous stimuli can increase or decrease nuclear receptor activity, and by virtue of 
this it will translate to drug metabolism and disposition proteins having inducible or 
repressible expression as they are the targets (Wang and LeCluyse, 2003).  
1.4.3.1.1 Regulation of Metabolic Enzymes 
RXR was the first orphan receptor discovered. As previously mentioned, it serves 
an important role for heterodimerization. These dimers can be classified as permissive or 
non-permissive, where permissive can be activated by RXR or its partner’s ligand, and 
non-permissive will only respond to the partner’s ligand (Giguère, 1999). RXR can also 
serve as a monomeric regulator of transcription through its ligand 9-cis-retinoic acid 
(Levin et al., 1992; Giguère, 1999). The pregnane X receptor (PXR) is well characterized 
in the literature due to its regulation of the human CYP3A subfamily. It has similar tissue 
expression patterns as CYP3A and is xenobiotic inducible, a necessary characteristic for 
a drug metabolizing enzyme regulator (Wang and LeCluyse, 2003). PXR has very little 
variation across species except for in the LBD, but still shares 76% sequence homology 
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with mouse and rat models (Wang and LeCluyse, 2003). Implications from this would be 
that the downstream regulatory pathways are very similar but the initiation portion may 
vary between species. PXR has also been shown to regulate the human CYP2B and 
MDR1 families, emphasizing its importance in drug metabolism and transport (Goodwin 
et al., 2001; Wang and LeCluyse, 2003).  
Of particular importance to this study is the regulation of CYP2B6. A system of 
PXR, a PXR-RXR heterodimer, and the constitutive androstane receptor (CAR) regulate 
CYP2B6 (Goodwin et al., 2001). The activation of CYP2B6 requires interaction at the 
nuclear receptor binding sites (NR1 and NR2) within the distal promoter phenobarbital-
responsive enhancer module (PBREM) (Czekaj, 2000; Goodwin et al., 2001). The rat 
homologs CYP2B1 and CYP2B2 are putatively regulated by a CAR-RXR heterodimer 
(Bing et al., 2014). The rat CYP2B promoter structure (Figure 1.2) follows the same map 
as human, as it contains the distal PBREM where CAR can bind the NR1 and NR2 sites 
(Shaw et al., 1996; Czekaj, 2000; Bing et al., 2014). The promoter is 2216 base pairs 
upstream of the transcriptional start site and contains a nuclear factor (NF-1) binding 
motif flanked by NR1 and NR2, all within a 51 base pair region (Shaw et al., 1996; 
Czekaj, 2000). There is significant sequence identity between the 2B1 and 2B2 promoters 
to the degree of 98-100% similarity. The transcription of 2B1 and 2B2 is phenobarbital 
(PB) inducible through an interaction of PB with the CAR-RXR heterodimer, causing 
interaction at the NR1 and NR2 sites in the PBREM (Honkakoski et al., 1998). The same 
phenomenon is believed to occur for CYP2B6 in humans, as CAR was shown to mediate 
PB inducibility in the HepG2 cell line (Sueyoshi et al., 1999). 
1.4.3.1.2 Regulation of Transporter Proteins 
In similar fashion to metabolic enzymes, PXR, CAR, and RXR, all play important 
roles in the nuclear regulation of transporter proteins (Urquhart et al., 2007). Starting 
with efflux transporters, P-gp is regulated by PXR as its inducer rifampin was able to 
upregulate it in the human intestinal goblet cell-like line, LS174T (Geick et al., 2001). Its 
expression may also be affected by the presence of monomeric CAR as a 2005 study 
showed the CAR/RXR heterodimer did not affect expression but CAR alone upregulated 
intestinal P-gp in vitro (Burk et al., 2005). The regulation of MRP2 was described in  
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Figure 1.2 - Schematic illustration of the PBREM binding region for the transcriptional 
regulation of CYP2B1. Images were modified from Servier Medical Art 
(http://www.servier.co.uk/medical-art-gallery).  
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 2002 via the incubation of HepG2 cells with activators for CAR, PXR, and the farnesoid 
X receptor (FXR) causing an increase in MRP2 transcriptional expression (Kast et al., 
2002). FXR has also been shown to regulate BSEP in both a mouse FXR knockout model 
and a human in vitro model by incubation of HepG2 cells with a FXR ligand (Sinal et al., 
2000; Ananthanarayanan et al., 2001). A previously unmentioned nuclear receptor, 
peroxisome proliferator-activated receptor gamma (PPAR𝛾), is able to dimerize with 
RXR and increase BCRP expression, shown with human dendritic cells in the presence of 
the PPAR𝛾 agonist rosiglitazone (Szatmari et al., 2006). The hepatocyte nuclear factor 1 
alpha (HNF1𝛼) is important for hepatic uptake of bile salts and bilirubin as it has been 
shown to regulate human OATP1B1 in Huh7 and HepG2 cell lines (Jung et al., 2001; 
Meyer zu Schwabedissen et al., 2010). Not limited to OATP1B1, OATP1B3 is also 
regulated by HNF1𝛼 along with a FXR/RXR heterodimer (Jung et al., 2001; 2002). Rat 
Ntcp, Oatp1a1 (Oatp1), 1a4 (Oatp2), and 1b2 (Oatp4) also appear to be regulated by 
HNF1𝛼 as a Tcf1-/- mouse line was shown to have bile acid and plasma cholesterol 
disposition irregularities secondary to lowered mRNA of the aforementioned transporters 
(Shih et al., 2001). Human and mouse NTCP/ntcp differ in their regulation as HNF1𝛼 did 
not affect expression levels; human NTCP was later discovered to be regulated by the 
glucocorticoid receptor (Jung et al., 2004; Eloranta et al., 2006).  
1.4.4 Altered Metabolism & Transport in Disease States 
Disease states are established to have an effect on CYP expression and function. It 
is reasonable to assume that an organ specific disease would have an effect on its 
metabolic function, as is the case with hepatic cirrhosis. Although the mechanism is not 
always clear, it is well documented that CYP function is altered in liver disease (George 
et al., 1995; Frye et al., 2006; Woolsey et al., 2015).  Altered metabolic function has also 
been seen in obesity, diabetes mellitus, congestive heart failure, and during infections 
(Nolin et al., 2003). This train of thought leads to the conclusion that metabolic and 
transporter function will be altered in renal tissues for CKD patients. Decreased renal 
function resulting in a lower GFR alone will lead to decreased drug exposure due to 
reductions in renal clearance, when combined with altered transporter and metabolic 
enzyme expression and function, the pharmacokinetics of drugs can be drastically altered 
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(Naud et al., 2011; Zhao et al., 2013).  Unless there has been experimental work 
presenting how clearance in the disease state is changed for a specific drug, the dosing 
adjustments will have to coincide with the known pharmacology of the drug and current 
creatinine clearance of the patient (Nolin, 2008).  
Precautions for renally cleared drugs being administered to CKD patients are 
fairly well characterized, however, recent advances have shown that non-renal routes 
such as hepatic elimination and intestinal absorption are impaired as well (Nolin et al., 
2003; Sun et al., 2004; Michaud et al., 2005; Sun et al., 2006; Naud et al., 2007; Nolin, 
2008; Velenosi et al., 2012). Putative mechanisms for this are transcriptional, 
translational, and epigenetic alterations in metabolic enzymes and transporter proteins 
due to increased levels of circulating inflammatory proteins and uremic toxins (Guévin et 
al., 2002; Dreisbach and Lertora, 2008; Nolin et al., 2008; Velenosi et al., 2012; Zhao et 
al., 2013; Velenosi et al., 2014; Ladda and Goralski, 2016). Both transport and 
metabolism at non-renal sites are affected along with altered plasma protein and tissue 
binding (Nolin et al., 2008; Dreisbach and Lertora, 2008). There is a reported 40% 
reduction in total hepatic CYP enzymes in CKD (Leblond et al., 2000). Activity of CYP 
enzymes is also significantly affected as assays such as the erythromycin breath test have 
shown a 35% decrease in CYP activity in rat models of CKD (Leblond et al., 2000). 
Inflammation is a common mechanism between disease states that has been shown to 
affect metabolic enzyme and transporter function (George et al., 1995; Nolin et al., 2008; 
Morgan et al., 2008; Huang et al., 2010). Cytokines have been shown to down-regulate 
CYP enzymes as well as transporters such as P-gp (Morgan et al., 2008). The more 
important mechanism in CKD is likely to be the high circulating uremic toxins. Studies 
have shown reversals of the down regulation upon kidney transplant but it is not seen to 
the same extent in hemodialysis as the protein-bound uremic toxins will not be removed 
as efficiently (Nolin et al., 2006; Nolin, 2008). This was illustrated by the quantification 
of 4β-hydroxycholesterol (an endogenous marker of CYP3A function) in CKD patients 
(Suzuki et al., 2013). There was a significant rise in plasma 4β-hydroxycholesterol 90 
and 180 days post-transplant compared to its formation rate prior to the transplant 
(Suzuki et al., 2013). 
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Significant reductions in the activity of rat CYP2C11, 3A1, and 3A2 secondary to 
lowered mRNA and protein levels of the respective isoenzymes has been reported in 
CKD (Leblond et al., 2001; Velenosi et al., 2012). The expression of rat CYP1A2, 
CYP2C6, and CYP2D have also been shown to be downregulated in CKD (Uchida et al., 
1995; Guévin et al., 2002; Rege et al., 2003). Work by Velenosi et al in 2014 showed 
that there are epigenetic differences as well as nuclear receptor alterations potentially 
contributing to the altered expression and activity of CYP enzymes in CKD. Chromatin 
Immunoprecipitaiton (ChIP) revealed RNA polymerase II and HNF4𝛼 binding to the 
promoter regions of CYP2C11 and CYP3A2 was decreased by approximately 70% 
(Velenosi et al., 2014). They also showed a large decrease in histone 3 acetylation in the 
promoter regions of CYP2C11 and 3A2 (Velenosi et al., 2014). The effect of CKD on rat 
CYP2B1 and 2B2 expression, activity, and regulation is currently unexplored.   
The altered expression and function of non-renal transporters has also been 
established in the literature. Specific uremic toxins were shown to decrease transport of 
erythromycin in rat hepatocytes, mostly affecting the OATP transporters (Sun et al., 
2004). Livers from rats with CRF showed a 25% increase in P-gp protein expression, a 
40% increase in Mrp2 mRNA expression, and a decrease in Oatp1a4 protein expression 
but no change in mRNA abundance (Naud et al., 2008). There is speculation however 
that Oatp1a4 function is also affected but it is currently unexplored in CKD (Sun et al., 
2006; Naud et al., 2008). Intestinal efflux transporters in rats, such as P-gp, Mrp2, and 
Mrp3 have been shown to be down regulated while enteric Oatp1a4 and Oatp1a5 (Oatp3) 
are not affected in CKD (Naud et al., 2007). Indoxyl sulfate and CMPF were shown to 
impede P-gp’s ability to transport cyclosporin in Caco2 cells, again pointing to a uremic 
toxin mediated mechanism (Shibata et al., 2000). A study in 2009 incubated rat 
hepatocytes and enterocytes with serum from human patients with ESRD (Nolin et al., 
2009). The results showed a decrease in hepatic Oatp1a4 protein expression but an 
increase for P-gp; enteric P-gp and CYP3A2 protein expression were both decreased 
while Oatp1a5 was not affected (Nolin et al., 2009). The same study also looked at the 
clearance of fexofenadine and found it was decreased, as it is transported by P-gp and 
Oatps (Nolin et al., 2009). 
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1.5 Statins 
The statins are the highest prescribed class of drugs in the world and are used in 
the clinic to treat hypercholesterolemia by lowering low-density lipoprotein (LDL)-C 
levels. The mechanism of action is to regulate hepatic cholesterol biosynthesis through 
inhibition of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase, which is the rate 
limiting enzyme for this process and used to reduce HMG-CoA to mevalonic acid 
(Nezasa et al., 2002; Knauer et al., 2010). They are noted for their efficacy in reducing 
the incidence of cardiovascular events (Levine et al., 1995). CKD patients are often 
prescribed statins as LDL-C lowering therapy is known to decrease CVD risk in stages 1-
3 (National Kidney Foundation, 2002; Colhoun et al., 2004).  
Statins have a low toxicity profile however there are reported cases with serious 
side effects. Skeletal muscle complications such as myalgia are the most common ADRs, 
occurring in 5-15% of patients (Sinzinger et al., 2002; Knauer et al., 2010). Instances of 
rhabdomyolysis have also been reported, albeit rarely, but can be life threatening through 
mass myocyte destruction resulting in acute renal failure (Zutt et al., 2014). Renal failure 
is caused by tubule obstruction and direct toxicity from myoglobin, which accumulates 
beyond plasma protein-binding capacity once the myocytes rupture (Zutt et al., 2014). 
Some statins are excreted mostly as unmetabolized parent compounds. This 
emphasizes the importance of drug transport in the regulation of their clearance. 
OATP1B1 is responsible for a significant portion of pravastatin and pitavastatin transport 
as a 1B1 SNP with lower activity caused a large increase in the area under the curve for a 
plasma concentration-time plot in humans (Nishizato et al., 2003; Chung et al., 2005).  
1.5.1 Rosuvastatin 
Rosuvastatin is touted to have the highest inhibitory proficiency for HMG-CoA 
reductase amongst the statins from in vitro work in rat hepatocytes (McTaggart et al., 
2001). It has also been shown to be more effective than atorvastatin, simvastatin, and 
pravastatin in terms of blood cholesterol reduction in the clinic (Olsson, 2001; JH Choi et 
al., 2007). The tissue distribution of rosuvastatin is localized to the liver and 88.3% of the 
drug excreted in the bile was the parent compound, indicating a low degree of 
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metabolism (Nezasa et al., 2002). The excretory pathway is therefore driven by transport, 
and specifically hepatic transport as 98% of an 5mg/kg orally administered dose was 
recovered in the feces, while only 0.4% is found in the urine (Nezasa et al., 2002).  
The main drug transporter for rosuvastatin is OATP1B1, accounting for 43-55% 
of uptake (Kitamura et al., 2008). A 2008 clinical study in the Korean population 
displayed the importance of OATP1B1 as the *15 SNP predisposed patients to higher 
plasma concentrations of rosuvastatin (JH Choi et al., 2007). Other significant OATP1B1 
SNPs for rosuvastatin pharmacokinetics include *5, *9, and *18 (Ho et al., 2006). 
Despite the importance of OATP1B1, there are other important transporters involved in 
its disposition. A study in 2006 elucidated that NTCP accounts for 35% of rosuvastatin 
transport in humans by comparing a sodium vs sodium-independent uptake assay (Ho et 
al., 2006). OATP1B3, OATP2B1, and OATP1A2 all have the capacity to transport 
rosuvastatin and this redundancy increases the safety of the drug as a OATP1B1 loss of 
function will not be as significant as it is for other statins such as pravastatin and 
pitavastatin (Lee et al., 2005; Ho et al., 2006; Kitamura et al., 2008). Efflux transport in 
humans falls under the jurisdiction of BCRP, MRP2, and P-gp, as all have shown affinity 
for rosuvastatin (Kitamura et al., 2008).  
There are species differences in the role of transporters for rosuvastatin. Uptake 
transport in rats is driven primarily by Oatp1a4, Oatp1a5, and Oatp1b2 (Ho et al., 2006). 
The largest discrepancy is that rat Ntcp does not efficiently transport rosuvastatin as it 
does in humans as transport was unaffected in a sodium-free buffer (Ho et al., 2006). Rat 
Oatp1a1, 1a4, 1a5, and 1b2 all show highly favourable interactions with rosuvastatin as a 
substrate (Ho et al., 2006). Canalicular transport is driven primarily by Mrp2 with Bcrp 
and Bsep having roles as well in sandwich cultured rat hepatocytes (Jemnitz et al., 2010). 
In conjunction with its limited metabolism and minimal renal clearance, rosuvastatin is a 
good probe substrate for hepatic OATP function (Knauer et al., 2010). The product 
monograph has dose reduction recommendations listed for patients with severe renal 
impairment, indicating potential pharmacokinetic alterations in the disease state 
(AstraZeneca 2012). Additionally contraindications for patients with active liver disease 
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are listed, insinuating that alterations to hepatic tissue may also lead to changes in 
rosuvastatin clearance (AstraZeneca 2012).  
1.6 Animal Models of CKD 
Animal models are used to study chronic conditions that normally take years to 
develop in humans, they can accelerate pathogenesis into a matter of weeks allowing for 
rapid assessment of disease conditions (Hewitson et al., 2008). Animal models can be 
used to elucidate mechanisms underlying pathologic states and to develop therapies 
within a feasible timeframe due to the accelerated disease development (Furness and 
Harris, 1994). There are a variety of currently validated CKD models, each attempting to 
replicate different CKD etiologies. There are surgical, nephrotoxic, immune-mediated, 
and metabolic models. 
There are three common surgical models to induce CKD including ureteric 
obstruction, sub-total nephrectomy or remnant kidney, and ischemic acute renal failure 
(Hewitson et al., 2008). Of the surgical models, sub-total nephrectomy is the most 
commonly used (Leblond et al., 2000; 2001; Hewitson et al., 2008; Velenosi et al., 
2012). There is also a ligation and ablation modification of this technique. The ablation 
procedure involves the removal of 2/3 of one kidney (typically the left), then 5 days post-
op complete ablation of the in-tact kidney is carried out, resulting in a 5/6 loss of total 
renal mass (Hewitson et al., 2008). The ligation version involves a uninephrectomy with 
subsequent ligation of 2/3 of the polar branches of the renal artery, simulating 
hypertensive kidney failure (Hewitson et al., 2008). Some groups do a hybrid of the 
ligation and ablation models to try and reduce variability between rats (Velenosi et al., 
2012). Problems arising from this model revolve around post-operative inflammation and 
the intricate nature of the procedure leading to a large window for human error and 
variability between animals. Sham-laparotomies can control for some of the 
inflammatory irregularities however there is still an appreciable chance for human error 
to persist between nephrectomized animals and laparotomy controls.  
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1.6.1 Nephrotoxic Models  
The kidney’s role in detoxification and clearance leaves it exposed to many toxins 
that may cause major renal damage. There are multiple currently validated nephrotoxic 
models including podocyte and tubular toxins, as well as tubular obstruction versions. 
These models typically have lower variability as they can be added to the diet of animals, 
causing renal damage based on consumption rates, therefore keeping renal damage 
proportional to weight. Larger animals will have larger kidneys, but will incur greater 
kidney damage due to increased appetite, theoretically controlling for size differences 
between animals. Folic acid or adenine supplements to food can cause CKD secondary to 
tubular obstruction. The adenine model of CKD was first developed in 1984 and involves 
long-term administration of standard rat chow supplemented with up to 0.75% adenine 
(Yokozawa et al., 1984; Terai et al., 2008). Renal damage occurs from the adenine 
metabolite, 2,8-dihydroxyadenine, precipitating and crystallizing in the proximal tubule 
epithelia (Hewitson et al., 2008; Ali et al., 2013). The resulting phenotype is a granular 
and enlarged kidney with apoptotic lesions and widespread fibrosis (Koeda et al., 1988; 
Tamagaki et al., 2006; Diwan et al., 2013). There are elevations in plasma urea and 
creatinine as well as reported azotemia (Diwan et al., 2013; Velenosi et al., 2016). The 
diet must be administered consistently for an extended period of time as recovery may 
occur after 2 weeks of treatment, after 4-6 weeks however the damage is irreversible as 
there is severe inflammation, fibrosis, and calcification of tubular basement membranes 
(Tamagaki et al., 2006; Hewitson et al., 2008). Although it reduces diversity in the 
degree of CKD between animals and eliminates the requirement for specialized and 
technical skill, there is one notable drawback to this model (Terai et al., 2008). It has 
been reported that there is limited food consumption within the first week of adenine 
administration, which makes pair-feeding a necessity for control animals (Terai et al., 
2008). Both surgical and nephrotoxic animal models of CKD have been shown to 
decrease selected drug metabolizing enzymes compared to pair-fed control animals 
(Leblond et al., 2001; Velenosi et al., 2012; 2014; Feere et al., 2015). 
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1.7 Objectives and Hypothesis 
Chronic kidney disease is a major global health burden. It can result in many 
comorbidities that require multiple prescriptions to manage them, leading to one of the 
highest pill burdens among chronic conditions. Several studies have shown altered renal 
and non-renal clearance of drugs in CKD, which leads to pharmacokinetic changes and 
commonly to severe adverse drug events. Many drugs have yet to be specified whether or 
not dosing regimens should be changed as it is unknown if their disposition pathway is 
affected by CKD. The altered clearance is a result of changes to the expression and 
function of metabolic enzymes and transporter proteins, both renal and non-renal. The 
putative mechanism for these alterations is the uremic condition that ensues in moderate 
and severe CKD. Specifically, gut-derived uremic toxins are proposed to cause the 
alterations in metabolism and transport. Better knowledge of the uremic state and how it 
affects drug metabolism and disposition is necessary.  
The objective of this project is to elucidate whether the removal of uremic toxins 
can recover the expression and function of transporter proteins and metabolic enzymes. 
As extensively outlined in previous sections, there is reason to believe gut-derived uremic 
toxins alter non-renal metabolism and transport. Thus the role specific uremic toxins play 
in the alteration of metabolism and transport will also be explored. The first aim of the 
study was completed using an adenine-induced model of CKD in male Wistar rats. 
Administration of the drug AST-120 was used to lower gut-derived uremic toxin levels in 
the animals. It is hypothesized that transporter protein as well as metabolic enzyme 
expression and function will be altered in CKD, and AST-120 will recover expression 
and function back to control levels by removing the aforementioned gut-derived uremic 
toxins. 
 The second portion of this study is the in vitro aspect. The purpose of this is to 
determine which individual uremic toxins, if any, are responsible for alterations in 
transport and metabolism. The human hepatocarcinoma cell line Huh7 will be incubated 
with toxins and the transporter probe drug, rosuvastatin. It is hypothesized that 
rosuvastatin uptake will be decreased in Huh7 cells when they are incubated with uremic 
toxins.  
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Chapter 2  
2 Methods 
2.1 CKD Rat Model 
Male Wistar rats were obtained from Charles River Laboratories (Wilmington, 
Massachusetts). They were allowed an acclimation period of at least 4 days while on a 
12-hour light cycle and were provided with Harlan 8640 Teklad 22/5 rodent diets (Harlan 
Laboratories: Madison, Wisconsin) and water ad libitum. All animal care protocols and 
procedures followed guidelines provided by the Western University Animal Care 
Committee and the Canadian Council on Animal Care (Appendix A).  
2.1.1 Study 1 – Hepatic and Intestinal Transport (7 Weeks) 
Male Wistar rats were used as the in vivo model. After a 5-day acclimation period 
animals were divided into 4 groups (n=10-14 per group), which determined their diet for 
the duration of the 7-week study. Control and control+AST-120 groups were pair-fed to 
the CKD and CKD+AST-120 rats. CKD and CKD+AST-120 were provided food ad 
libitum throughout the 7 weeks. Control rats were fed standard rat chow (Harlan 
Laboratories: Madison, Wisconsin) for the entire study. CKD rats were fed standard rat 
chow supplemented with 0.7% adenine (Harlan Laboratories: Madison, Wisconsin) for 
the first 4 weeks, followed by 3 weeks of control diet. Control+AST-120 rats were fed 
standard rat chow for the initial 4 weeks but were changed to the same diet mixed with 
8% AST-120 (provided by Kureha Corporation: Tokyo, Japan) for the remaining 3 
weeks. The CKD+AST-120 group received the same diet as the CKD rats for the first 4 
weeks and were provided with standard rat chow supplemented with 8% AST-120 for the 
final 3 weeks. On the last day of the study the rats were injected with either 5mg/kg of 
rosuvastatin (acquired from Toronto Research Chemicals: Toronto, Ontario) or 10mg/kg 
of fexofenadine intravenously (acquired from Toronto Research Chemicals: Toronto, 
Ontario). Sacrifice occurred 2-hours post-injection via isoflurane administration and 
subsequent decapitation. Liver, heart, kidney, small intestine, and pancreas were 
harvested, flash frozen in liquid nitrogen, and stored at -80ºC. Whole blood was collected 
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in heparin coated tubes, centrifuged at 1300 RCF for 10 minutes to separate plasma, then 
the supernatant was stored at -20ºC.  Serum urea and creatinine levels were determined 
by the London Laboratory Services Group by standard methods.  
2.1.2 Study 2 – Hepatic Transport (8 Weeks) 
Some differences in terms of severity of CKD were noted in the 7-week study 
compared to previous studies from our lab that utilized an 8-week protocol. We therefore 
decided to repeat the transport study with the more severe model of CKD. Wistar rats 
were used again as the in vivo model. The rats were divided into 4 groups (n=6-8 per 
group), which determined their diet for the span of the 8-week study. Control and 
control+AST-120 rats were pair-fed to CKD and CKD+AST-120 groups. Control rats 
received standard rat chow for the full 8 weeks while CKD rats were provided standard 
chow with 0.7% adenine for 5 weeks, and control food for the remaining 3 weeks. 
Control+AST-120 and CKD+AST-120 rats were provided with standard rat chow and 
standard rat chow with 0.7% adenine respectively until the end of week 5. They were 
then both switched to standard rat chow augmented with 8% AST-120 until the 
conclusion of the study. On the final day the rats were injected with 5mg/kg rosuvastatin. 
Two-hours post-injection they were sacrificed through isoflurane exposure and 
subsequent decapitation. Whole blood, liver, heart, kidney, small intestine, and pancreatic 
tissues were harvested and snap frozen in liquid nitrogen, then stored at -80ºC. Whole 
blood was collected in heparin coated tubes, centrifuged at 1300 RCF for 10 minutes and 
then the plasma layer was extracted and stored at -20ºC.  
2.1.3 Study 3 – Hepatic Metabolizing Enzymes (8 Weeks) 
Another replicate of the rat model from study 2 was completed previously in our 
lab with the animals being divided into the same 4 groups (n=9-12 per group) (Velenosi 
et al., 2014; 2016). They did not receive injections and the same tissues were collected as 
described above. 
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2.2 Real-Time PCR 
Sample preparation for qPCR was preceded by an RNA extraction from hepatic or 
intestinal tissue. A phenol-chloroform extraction was performed while employing 
guanidine isothiocyanate as a chaotropic agent by using Life Technologies’ TRIzol 
reagent (Burlington, Ontario). RNA was quantified post-extraction using a nanodrop 
spectrophotometer from Thermo Scientific (West Palm Beach, Florida). Consistent 
concentrations were attained post-nanodrop by adding 1 µg of RNA to qScript cDNA 
supermix containing reverse transcriptase (Quanta Biosciences, Gaithersburg, Maryland). 
This mixture was subject to thermal cycling in order to synthesize cDNA.  
2.2.1 Primer Validation 
Primers were designed through the use of NCBI Primer BLAST. PCR 
amplification in conjunction with SYBR safe gel electrophoresis was completed for each 
potential primer set to check primer specificity. Primer efficiency was determined by 
serially diluting cDNA and acquiring cycle threshold (Ct) values using qPCR. Efficiency 
was calculated using the equation 10^(-1/slope)-1, with resulting values from 80-120% 
deemed acceptable. Primer sets developed and validated for this project are listed in 
Table 2.1.  
2.2.2 Quantification 
The cDNA of interest was diluted 1:40 and a master mix was created for each 
gene of interest using a SYBR green supermix in conjunction with forward and reverse 
primers for the gene. Samples were pipetted in triplicate into a 384-well plate, 5 µl of 
cDNA and 7 µl of master mix were aliquoted to each well. An optical density lid was 
applied once all samples were in the plate. The plate was then put on a plate shaker for 1 
minute and subsequently centrifuged at 1000 rpm for 1 minute at room temperature. A 
Bio-Rad thermocycler (Hercules, California) was used to complete the denaturation, 
annealing, and elongation steps. Relative RNA expression was determined using the 
∆∆Ct method while using β-Actin and villin as the housekeeping genes for hepatic and 
enteric tissue respectively (Schmittgen and Livak, 2008). For Huh7 cell work 18s rRNA 
was used as the housekeeping gene. All values were relative to control groups.  
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  Table 2.1 - Primer sets for real-time PCR 
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2.3 Western Blot 
The western blot technique was performed to determine relative protein 
expression levels in order to elucidate translational activity for genes of interest.  
2.3.1 Microsome Isolation 
The generation of rat liver microsomes followed a protocol described previously 
(Velenosi et al., 2012). Rat livers were taken from -80ºC storage and a portion was 
excised and washed with 0.9% NaCl while on ice then submerged in 1.15% KCl + 1mM 
ethylenediaminetetraacetic acid (EDTA). Tissue was homogenized using a T 10 Basic 
Ultra-TURRAX dispersing instrument from IKA Laboratory Technology (Sigma 
Aldrich: St. Louis, Missouri). The microsomal layer was separated using differential 
centrifugation with an initial spin at 9000g for 20 minutes while at 4ºC. The supernatant 
was collected and spun at 105000g for 60 minutes and at 4ºC. The ensuing microsomal 
pellet was suspended in 0.1M potassium phosphate buffer with 20% glycerol at pH=7.4. 
Samples were aliquoted and stored at -80ºC. 
2.3.2 Pierce BCA Assay 
Protein quantification was completed using the Pierce Bicinchoninic Acid Assay 
kit, obtained from Fischer Scientific (Waltham, Massachusetts). The principle being that 
the peptide bonds in protein will reduce the Cu2+ in copper (II) sulfate to Cu+. 
Bicinchoninic molecules will chelate with Cu+ in an alkaline environment, resulting in a 
purple coloured complex that has strong absorptive properties at 526 nm. The production 
of the purple complex is proportional to the amount of protein in the sample.   
2.3.3 Gel Electrophoresis 
The gels used were 10% polyacrylamide for resolving and 4% for stacking while 
both contained 0.1% sodium dodecyl sulfate. Ammonium persulfate and TEMED (Bio 
Basic Inc: Markham, Ontario) were used as polymerization agents. Samples were 
prepared by adding 20 µg of microsomal protein to a mixture containing the reducing 
agent beta-mercaptoethanol and western blot sample buffer containing 10% sodium 
dodecyl sulfate, 26% glycerol, and 0.5% bromophenol blue. Subsequent incubation at 
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80ºC for 20 minutes was carried out to achieve sufficient protein denaturation. Samples 
were then loaded into wells in the gel and an electrical force of 150V was applied for 45 
minutes or until protein migration presented with adequate separation. The gels were then 
put into a transfer cassette ventral to a nitrocellulose membrane and submersed in Bio-
Rad transfer buffer. A current was applied at 150V for 90 minutes. The membrane was 
blocked with PBS + 0.15% tween (PBS-T) containing 5% skim milk powder and 0.6% 
bovine serum albumin for 60 minutes before being washed three times with PBS-T. 
Primary antibodies were applied and allowed to incubate at 4ºC overnight. Primary 
antibodies used were a monoclonal mouse anti-rat CYP2B primary antibody from Detroit 
R&D Inc. (Detroit, Michigan) which was diluted 1:2000 with PBS-T containing 5% skim 
milk powder and a rabbit anti-rat polyclonal Oatp1a4 primary antibody from Millipore 
(Billerica, Massachusetts) which was diluted 1:1250 with PBS-T containing 0.6% bovine 
serum albumin. Membranes were washed the next day and incubated with a secondary 
antibody conjugated to horseradish peroxidase (Santa Cruz Biotechnology Inc: Santa 
Cruz, California) for 60 minutes. The blots were washed again before adding Luminata 
Forte western blot HRP substrate (Millipore: Billerica, Massachusetts) for 
chemiluminescence. The platform used to visualize the immunoblots was a Bio-Rad 
VersaDoc Imaging System (Hercules, California). Blots were then stripped and washed 
before adding a monoclonal mouse anti-beta-actin primary antibody conjugated to HRP, 
obtained from Sigma Aldrich and diluted 1:50000. Relative gene expression could 
therefore be determined to baseline protein expression using beta actin while being 
standardized with a loading control. Densitometry was completed using the Quantity One 
program from Bio-Rad (Hercules, California), values were relative to control.  
2.4 Rosuvastatin Quantification 
2.4.1 Plasma Extraction 
Plasma was obtained after subjecting whole blood to centrifugation at 1300 RCF 
for 10 minutes and collecting the supernatant. The plasma was subjected to solid phase 
extraction via Phenomenex (Torrance, California) Strata-X polymeric reversed phase 
packings, this step included the addition of internal standard (D3-Rosuvastatin at 100nM) 
with subsequent exposure to a nitrogen evaporator at 40ºC. Samples were reconstituted in 
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100µl of 70% water and 30% acetonitrile, then subject to quantification by a Waters 
Acuity I Class ultra-performance liquid chromatography (UPLC) system coupled to a 
XEVO G2-S quadrupole time-of-flight (QTOF) mass spectrometer (Waters Corporation: 
Milford, Massachusetts). The standard curve used for absolute quantification was serially 
diluted from 5000nM to 10nM and was extracted from human plasma in order to control 
for matrix effects. Quality controls were completed every 10 samples at a concentration 
of 125nM.  
2.4.2 Hepatic Extraction 
Segments of whole liver were obtained using surgical blades and these pieces 
were homogenized using a pestle and tube in acetonitrile containing internal standard 
(D3-Rosuvastatin, acquired from Toronto Research Chemicals: Toronto, Ontario). 
Samples were then vortexed and incubated for 20 minutes on ice. Next they were 
centrifuged at 14000 rpm and the supernatant was removed and diluted prior to 
quantification by UPLC-MS. 
2.4.3 UPLC-MS Conditions 
An Acuity bridged ethylene hybrid (BEH) C18 column (2.1x50mm, 1.7µm) from Waters 
(Milford, Massachusetts) was used with a flow rate of 0.5mL/min at 40C with sample 
injection volume set to 10µl. Water with 0.01% formic acid was used as solvent A and 
acetonitrile with 0.01% formic acid served as solvent B. A gradient of solvent B went 
from 30% to 50% in 2 minutes, 50-80% from 2 to 2.1 minutes, followed by 80% B for 
one minute and a one-minute equilibration at 30% B. The lock-mass spray solution was 
500pg/µl of leucine enkephalin (556.2771Da in positive ionization) in 50% acetonitrile 
with 0.1% formic acid, and the mass spectrometer was calibrated with 0.5mM sodium 
formate. The lock spray operated with a scan time of 0.3 seconds and at an interval of ten 
seconds with a mass window of 0.5Da. Electrospray ionization parameters included a 
capillary spray voltage of 0.5kV; desolvation gas flow of 1000L/h at 600C; cone gas 
flow of 50L/h with a source temperature of 150C; sampling cone and source offset 
voltages at 40V and 80V, respectively. Data was acquired using positive ionization and 
the instrument was run in resolution mode with a mass range from 50 to 1200Da with 0.1 
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scans per second. 
2.5 Enzyme Function Assay 
Rat liver microsomes were removed from -80ºC storage and aliquoted into a 96-
well plate, allowing for each sample to be completed in duplicate. The metabolism 
reaction mixture contained a microsomal buffer (50mM KH2PO4 buffer with 5mM 
MgCl2 at pH=7.4), bupropion (Toronto Research Chemicals: Toronto, Ontario), rat liver 
microsomes, and nicotinamide adenine dinucleotide phosphate (NADPH) was added last 
to commence the reaction. Wells deprived of NADPH were used as negative controls. 
The conversion of bupropion to hydroxybupropion was used to determine CYP2B 
enzyme function as previously described in the literature (Pekthong et al., 2012). 
2.5.1 Validation  
Three preliminary validation tests were completed prior to running the experiment 
to its entirety. These tests varied one of three independent variables which include time, 
microsome concentration, and drug concentration. The appropriate time-point to stop the 
reaction was ascertained to be 30 minutes, while the microsomal concentration was 
0.5mg/ml, and the range of concentrations for bupropion were from 10μM to 500μM. 
2.5.2 Hydroxybupropion Quantification  
The incubation temperature during the assay was 37°C. In order to stop the 
reaction at 30 minutes, ice-cold acetonitrile (containing flurazepam as an internal 
standard at 40ng/ml) was added at a ratio of 3:1 acetonitrile to sample. Samples were 
spun at 3000rpm for 5 minutes, after which the supernatant was removed and diluted 5:1 
in water before being run on the UPLC-MS system for quantification. Dilution was 
necessary to reduce ionization suppression from the KH2PO4 buffer. A standard curve 
was generated by serially diluting concentrations from 50µM to 50nM with sample 
injection volumes set at 5µl. An Acuity BEH C18 column (2.1x50mm, 1.7µm) from 
Waters (Milford, Massachusetts) was used with a flow rate of 0.6mL/min at 40C. Water 
with 0.01% formic acid was used as solvent A and acetonitrile with 0.01% formic acid 
served as solvent B. A gradient of solvent B started as isocratic at 20% until 1.75 
minutes, it then increased to 50% from 1.75 to 2.5 minutes, 50-80% from 2.5 to 2.51 
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minutes, followed by 80% B for one minute, then 80-20% from 3.5 to 3.51; subsequently 
a 1.5-minute equilibration at 20% B took place. The lock-mass spray solution was 
500pg/μL of leucine enkephalin (556.2771Da in positive ionization) in 50% acetonitrile 
with 0.1% formic acid, and the mass spectrometer was calibrated with 0.5 mM sodium 
formate. The lock spray operated with a scan time of 0.3 seconds and at an interval of ten 
seconds with a mass window of 0.5Da. Electrospray ionization parameters included a 
capillary spray voltage of 0.5 kV; desolvation gas flow of 1000L/h at 600C; cone gas 
flow of 50L/h with a source temperature of 150C; sampling cone and source offset 
voltages at 40V and 80V, respectively. Data was acquired using positive ionization and 
the instrument was run in resolution mode with a mass range from 50 to 1200Da with 0.1 
scans per second. Results were plotted on a Michaelis-Menten enzyme kinetics graph to 
display bupropion metabolism in µM vs pmol/min/mg of CYP protein. 
2.6 Chromatin Immunoprecipitation 
Chromatin immunoprecipitation was performed on hepatic tissue extracted from 
Wistar rats according to a previously described method with subsequent modifications 
that are also described in the literature (Sohi et al., 2011; Velenosi et al., 2014). Tissue 
was homogenized in 1% formaldehyde solution that contained protease inhibitor to 
crosslink DNA to protein. After a 10-minute incubation at room temperature, 1M glycine 
in PBS was added to attenuate crosslinking. Samples were subsequently spun at 3000rpm 
for 5-minutes at room temperature, the supernatant was removed and 1ml of PBS was 
added. Samples were vortexed then spun at 3000rpm for 5 minutes, the supernatant was 
aspirated and 500µl of lysis buffer was added. After a 20-minute incubation at 4ºC, 500µl 
of ChIP dilution buffer was added. Samples were then sonicated at 30 AMP for 20 one-
second pulses to shear the DNA. Next they were centrifuged at 12,500rpm for 10-minutes 
at 4ºC, after which the supernatant was diluted 1:10 with ChIP dilution buffer. The 
extracted chromatin was pre-cleared for 2 hours at 4ºC with a protein A/G agarose and 
salmon sperm slurry. After centrifugation at 14000rpm for 5-minutes at 4ºC the 
supernatant was removed and the antibody of interest was added for an overnight 
incubation at 4ºC. Antibodies included a monoclonal mouse anti-rat RNA polymerase II 
(1µg per aliquot, 05-623, Millipore: Billercia, Massachusetts), polyclonal rabbit anti-rat 
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CAR (5µg per aliquot, sc-13065, Santa Cruz: Dallas, Texas), and anti-rat IgG from both 
mouse and rabbit that were procured from Millipore (12-371) and Santa Cruz (sc-2027) 
respectively. Aliquots to control for non-specific binding received an identical amount of 
non-immune IgG from the same host species as the antibody of interest. After a series of 
washes and spins, the chromatin was eluted and the crosslinks were reversed during a 4-
hour 65ºC incubation. A phenol-chloroform-isoamyl solution was used to separate 
chromatin, which was precipitated using ethanol and 3M sodium acetate at -20ºC 
overnight. Samples were dried down the next day and reconstituted in TE buffer for real-
time PCR analysis. Primer sets were designed to amplify the RNA polymerase II and 
CAR binding region at the CYP2B1 promoter (Table 2.1). Amplification of the RNA 
polymerase II binding region to the CYP3A2 promoter was used as a positive control and 
the primer sets were published by Velenosi et al in 2014.  
2.7 Huh7 Cell Line 
The human hepato-carcinoma cell line Huh7 was grown to one week post-
confluency for the purposes of this work as previously described (Sivertsson et al., 2010). 
Cells were taken from liquid nitrogen storage and thawed in a water bath at 37˚C. They 
were then pipetted into a flask which was subsequently filled with 10ml of Dulbecco’s 
Modified Eagle’s Medium + 10% fetal bovine serum and 0.9% w/v 
penicillin/streptomycin, the cells were left to incubate at 37˚C with 5% CO2. Once the 
cells were adhered to the flask (12-18 hours) the current media was aspirated to remove 
DMSO used for cell storage, new media was provided immediately. Media was changed 
every 2 days until the cells reached confluency, at which point they were split into 6-well 
or 12-well plates. To split the cells, media was aspirated and 10ml of PBS was added to 
wash the remaining media off. This was then aspirated and 3ml of trypsin was applied 
with an accompanying incubation for 5 minutes at 37˚C with 5% CO2. Once the cell 
adherence to the plate was diminished they were removed from the incubator and subject 
to gentle physical force do ensure the maximal number stayed in suspension. Media was 
then added (6ml) to inactivate trypsin. The mixture was transferred to a 15ml falcon tube 
which allowed gentle rotation of the cells to form a homogenous fluid to aliquot into 
plates or a new flask.  
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2.7.1 Characterization 
The Huh7 cell line has been previously characterized for metabolizing enzymes 
and transport proteins in the literature (Sivertsson et al., 2010). We reconfirmed that our 
cells followed the same RNA expression patterns for NCTP, BCRP, and OATP1B1 using 
real-time PCR. Samples were normalized to 18s rRNA as a housekeeping gene and then 
compared to human liver expression of the same transcripts.  
2.7.2 Uptake Transport and Uremic Toxin Incubation 
Cells were cultured for one week post-confluency in order to optimize transporter 
expression and all plates were replicated in triplicate (Sivertsson et al., 2010). Validation 
assays for transporter exposure time and rosuvastatin concentration were completed prior 
to the uremic toxin incubation experiments. Time points of 0.5, 1, 5, 10, 15, and 20 
minutes were evaluated, 10 minutes was selected due to linear transport kinetics at this 
time. To determine the optimal drug concentration an assay was performed to estimate 
the affinity of OATP1B1 for rosuvastatin. Concentrations of 1, 2, 5, 10 and 20µM were 
used due to an approximation of OATP1B1 enzyme affinity (Km) for rosuvastatin to be 
5µM from the literature (Ho et al., 2006). The last component of this study involved 
incubating the Huh7 cells with uremic toxins and rosuvastatin concurrently to determine 
whether there was a change from control. The toxins used and their respective 
concentrations were determined from the literature to approximate those measured in 
CKD patients and are as follows: 210µM indoxyl sulfate, 220µM p-cresyl sulfate, 
500µM hippuric acid, 40µM CMPF, 2µM methyl guanidate, 2mM creatinine, 80mM 
urea, 8µM guanidinosuccinic acid, 23µM phenyl sulfate, and 2µM 4-ethyl phenyl sulfate 
(Vanholder et al., 2003; Duranton et al., 2012). Cells were treated with individual toxins 
plus rosuvastatin, as well as a cocktail comprised of all the aforementioned toxins in 
addition to rosuvastatin. All of the toxins and rosuvastatin were dissolved in Hank’s 
Buffered Salt solution (HBSS).  
Cell uptake work was carried out according to the following protocol. The first 
step was to aspirate media and wash with PBS, the PBS was then removed and uremic 
toxins listed above added along with 5 µM rosuvastatin for 10 minutes. Subsequent 
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revisions to the protocol included a 2 hour preincubation with the uremic toxins. Upon 
completion of the pretreatment, either drug or drug with uremic toxin was added. 
Rosuvastatin was allowed to incubate for 10 minutes at 37ºC, after which the wells were 
aspirated and ice-cold HBSS was then added to wash and discontinue transport. Cells 
were then lysed using 0.2N NaOH containing internal standard (D3 Rosuvastatin). 
Cessation of lysis was achieved by neutralizing the solutions with 1N HCl. Samples were 
subsequently aliquoted and subjected to sonication to ensure maximal cell lysis. The final 
step was to perform solid-phase extraction to prepare the samples for quantification by 
UPLC-MS using the same rosuvastatin quantification conditions as described in section 
2.4.3. 
2.7.3 Uremic Toxin Incubation and Transcriptional Expression 
The expression of CYP2B6 was assessed at the mRNA level after a 24-hour 
incubation with various uremic toxins including guanidinosuccinic acid, methyl 
guanidate, CMPF, hippuric acid, urea, creatinine, indole-3-acetic acid, p-cresyl sulfate, 
indoxyl sulfate, and p-cresol. The incubation of the uremic toxins on the cells was 
conducted by another student in the lab (Velenosi et al. unpublished). Briefly, the cells 
were grown until 4 weeks post-confluency using the same medium mentioned previously. 
The cells were treated with the highest levels of uremic toxins reported in humans: 
creatinine (2121.6µM), p-cresyl sulfate (186.1µM), CMPF (391.7µM), guanidinosuccinic 
acid (268.6µM), hippuric acid (2631.3µM), indole-3-acetic acid (51.9µM), indoxyl 
sulfate (1113.2µM), methylguanidine (24.9µM), urea (76.6µM), and in a cocktail 
containing all of the toxins at their respective concentrations (Vanholder et al., 2003). 
The incubation was performed in the previously described maintenance media but 
excluding fetal bovine serum. An RNA extraction was performed as described above, and 
then real-time PCR using the CYP2B6 primer listed in table 2.1 with 18s rRNA as the 
housekeeping gene.  
2.8 Statistical Analysis 
Statistical analysis was performed using a one-way ANOVA with subsequent use 
of either Tukey’s or Dunnet’s post-hoc test. Data is displayed mean ± the standard error 
50 
 
of the mean with p<0.05 being the threshold for statistical significance. GraphPad Prism 
version 6.0 software was used for statistical analysis and generation of graphs.   
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Chapter 3  
3 Results 
3.1 Drug Transport in a 7-week in vivo CKD Model  
3.1.1 Assessment of Kidney Damage 
Plasma urea and creatinine were significantly increased in the CKD group compared to 
control and control+AST-120 (p<0.0001) (Figure 3.1). There was a 5.9 fold increase in 
urea from CKD animals compared to control and a 6.3 fold increase in creatinine. Urea 
was significantly higher in CKD compared to CKD+AST-120 (p<0.05), CKD+AST-120 
was not significantly greater than control or control+AST-120 however, despite a 3.4 fold 
increase compared to control. CKD+AST-120 was significantly greater than control 
(p<0.01) for plasma creatinine and differed from control+AST-120 significantly as well 
(p<0.05).  
3.1.2 Transporter Expression and Function 
No significance was seen between groups pertaining to the relative hepatic mRNA 
expression of Ntcp, P-gp, or Oatp1b2 (Figure 3.2). Bsep (Figure 3.2B) was significantly 
lower in control+AST-120 compared to control (p<0.05), and significantly higher in 
CKD+AST-120 compared to control+AST-120 (p<0.01). The relative enteric mRNA 
expression of P-gp, Bcrp, Mrp2, and CYP3A2 showed no significant differences between 
groups (Figure 3.3). Hepatic transporter function was determined by calculating the liver 
to plasma ratio of rosuvastatin in the animals. No differences were observed between 
groups for the transport of rosuvastatin (Figure 3.4).  
There was no difference in the hepatic mRNA expression of Oatp1a4 between groups 
(Figure 3.5A). CKD animals showed a 25% decrease in expression compared to control 
that was not observed in CKD+AST-120 however. There was also a significant 
correlation between increasing serum creatinine and decreasing Oatp1a4 expression 
(r2=0.2095, Figure 3.5B).  
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Figure 3.1 - Plasma urea (A) and creatinine (B) levels in control, CKD, control+AST-
120, and CKD+AST-120 wistar rats after a 7 week study. Presented as mean ± SEM, 
n=10-14 per group, ****p <0.0001, **p<0.01, ††††p<0.0001, †p<0.05. Plasma urea was 
significantly different between CKD and CKD+AST-120, CKD is also significantly 
different from control and control+AST-120 following Tukey’s post-hoc test. Creatinine 
was significantly different when comparing CKD or CKD+AST-120 to control or 
control+AST-120 using Tukey’s post-hoc test. * is relative to control, † is relative to 
control+AST-120. 
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Figure 3.2 - Relative mRNA expression of hepatic transporters in a 7-week CKD model. 
Panels A through D display control, control+AST-120, CKD and CKD+AST-120 in 
wistar rats. Presented as mean ± SEM, n=10-14 per group, *p <0.05, ††p<0.01. β-actin 
was used as the housekeeping gene for Ntcp (A), Bsep (B), P-gp (C), and Oatp1b2 (D). 
Control+AST-120 was significantly lower than control for Bsep and CKD+AST-120 was 
significantly higher than control+AST-120. * is relative to control, † is relative to 
control+AST-120. 
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Figure 3.3 - Relative mRNA expression of intestinal P-gp (A), Bcrp (B), Mrp2 (C), and 
CYP3A2 (D) in control, control+AST-120, CKD and CKD+AST-120 in wistar rats. 
Presented as mean ± SEM, n=10-14 per group. Villin was used as the housekeeping 
gene. 
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Figure 3.4 - Liver to plasma ratio of rosuvastatin in control, control+AST-120, 
CKD, and CKD+AST-120 wistar rats. Analyzed by a one-way ANOVA and 
Tukey’s post-hoc test. Presented as mean ± SEM, n=10-14 per group. 
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Figure 3.5 - (A) Relative liver Oatp1a4 mRNA expression in control, control+AST-120, 
CKD, and CKD+AST-120 in wistar rats. Presented as mean ± SEM, n=10-14 per group. 
β-actin was used as the housekeeping gene. (B) Linear regression of control and CKD 
rats displaying the correlation between creatinine and Oatp1a4. Oatp1a4 was 
significantly correlated with kidney function (p<0.05), r2 = 0.2095. 
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3.2 Drug Transport in an 8-week in vivo Model of CKD  
3.2.1 Assessment of Kidney Damage  
Serum urea in CKD and CKD+AST-120 groups was significantly higher (p<0.01) than 
both control and control+AST-120 groups (Figure 3.6A). There was a 6.2 fold increase in 
plasma urea from CKD animals compared to control. Serum creatinine from CKD and 
CKD+AST-120 was also significantly different (p<0.0001) than control and 
control+AST-120 groups (Figure 3.6B). This includes a 10.8 fold increase in creatinine 
from CKD animals when compared to control. 
3.2.2 Transporter Expression and Function  
The mRNA expression of Oatp1a4 and Bcrp were analyzed in hepatic tissue (Figure 
3.7A). CKD animals had significantly lower (p<0.05) Oatp1a4 expression compared to 
controls that manifested as a 50% reduction of the transcript. There were no differences 
between the other groups for Oatp1a4. The relative mRNA expression of hepatic Bcrp 
was significantly lower (p<0.05) in control+AST-120 and CKD+AST-120 compared to 
both control and CKD groups (Figure 3.7B).  
The liver to plasma ratio of rosuvastatin was not significantly different between groups 
(Figure 3.8). Although there was no significance, a two-fold increase in the liver to 
plasma ratio of rosuvastatin in CKD compared to control was observed.  
  
58 
 
  
Figure 3.6 - Plasma urea (A) and creatinine (B) levels in control, CKD, control+AST-
120, and CKD+AST-120 wistar rats after an 8 week study. Presented as mean ± SEM, 
n=6-8 per group, **p<0.01, ****p<0.0001, ††p<0.01, ††††p<0.0001. Both plasma urea and 
creatinine were significantly different when comparing CKD or CKD+AST-120 to 
control or control+AST-120 using Tukey’s post-hoc test. * is relative to control, † is 
relative to control+AST-120. 
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Figure 3.7 - Relative mRNA expression of hepatic Oatp1a4 (A) and Bcrp (B) in an 8 
week model of adenine induced CKD. Graphs A and B display control, control+AST, 
CKD and CKD+AST-120 in wistar rats. Presented as mean ± SEM, n=6-8 per group, 
*p<0.05, †p<0.05. β-actin was used as the housekeeping gene for Oatp1a4 and Bcrp. 
Oatp1a4 expression in CKD animals was significantly lower than that of control animals. 
Control+AST-120 and CKD+AST-120 had significantly lower Bcrp expression compared 
to both control and CKD animals. * is relative to control, † is relative to CKD. 
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Figure 3.8 - Liver to plasma ratio of rosuvastatin in control, control+AST-120, 
CKD, and CKD+AST-120 wistar rats. Analyzed by a one-way ANOVA and 
Tukey’s post-hoc test. Presented as mean ± SEM, n=6-8 per group. 
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3.3 Drug Metabolism in an 8-week in vivo CKD Model 
3.3.1 Assessment of Kidney Damage 
Serum urea in CKD and CKD+AST-120 groups was significantly different (p<0.0001) 
from both control and control+AST-120 groups (Figure 3.9A). There was an 8.7 fold 
increase in plasma urea from CKD animals compared to control. Serum creatinine from 
CKD and CKD+AST-120 was also significantly different (p<0.0001) from control and 
control+AST-120 groups (Figure 3.9B). This includes a 9.1 fold increase in creatinine 
from CKD animals when compared to control. 
3.3.2 Hepatic Oatp Transcriptional Expression 
Oatp1a1 mRNA levels were significantly decreased (p<0.0001) in CKD relative to 
control (Figure 3.10A). CKD+AST-120 and control+AST-120 also significantly 
decreased (p<0.001 and p<0.05) respectively) relative to control expression. The 
expression of Oatp1a4 was significantly declined (p<0.05) by 45% and 43.5% in CKD 
relative to control and CKD+AST-120 respectively (Figure 3.10B). CKD animals also 
differed from CKD+AST-120 significantly (p<0.01). There was no significance between 
groups for either of Oatp1a5 or Oatp1b2.  
3.3.3 CYP2B Transcriptional Expression 
The expression of CYP2B1 showed significant differences (p<0.001) between control 
and both CKD and CKD+AST-120 groups (Figure 3.11A). CKD animals showed an 
average decrease in expression of 87.4% when compared to control rats. Control+AST-
120 mRNA expression was also significantly lower (p<0.05) relative to control.  
CYP2B2 showed a significant decrease (p<0.05) in mRNA expression between 
control+AST-120 and CKD animals (Figure 3.11B). Control+AST-120 and CKD+AST-
120 were 70% and 61% lower than control respectively.  
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Figure 3.9 - Plasma urea (A) and creatinine (B) levels in control, CKD, control+AST-
120, and CKD+AST-120 wistar rats after an 8 week study. Presented as mean ± SEM, 
n=9-12 per group, ****p<0.0001, ††††p<0.0001. Both plasma urea and creatinine were 
significantly different when comparing CKD or CKD+AST-120 to control or 
control+AST-120 using Tukey’s post-hoc test. * is relative to control, † is relative to 
control+AST-120. 
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Figure 3.10 - Relative mRNA expression of hepatic transporters in an 8-week CKD 
model. Panels A through D display control, control+AST, CKD and CKD+AST-120 in 
wistar rats. Presented as mean ± SEM, n=9-12 per group, *p <0.05, ***p<0.001, 
****p<0.0001, ††p<0.01. β-actin was used as the housekeeping gene for Oatp1a1 (A), 
Oatp1a4 (B), Oatp1a5 (C), and Oatp1b2 (D). Oatp1a1 expression was significantly lower 
in all groups relative to control, determined by Tukey’s post-hoc test. The expression of 
Oatp1a4 in CKD was significantly lower than all other groups according to Tukey’s post-
hoc test. * is relative to control, † is relative to control+AST-120. 
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Figure 3.11 - Relative mRNA expression of CYP2B1 (A) and CYP2B2 (B) in an 8-
week CKD model. Panels A and B display control, control+AST, CKD and CKD+AST-
120 in wistar rats. Presented as mean ± SEM, n=9-12 per group, *p <0.05, ***p<0.001, 
†p<0.05. β-actin was used as the housekeeping gene for CYP2B1 and CYP2B2. CYP2B1 
expression was significantly lower in all other groups relative to control, as determined 
by Tukey’s post-hoc test. The expression of CYP2B2 in the control+AST-120 group was 
significantly lower than the CKD rats according to Tukey’s post-hoc test. * is relative to 
control, † is relative to control+AST-120. 
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3.3.4 CYP2B Protein Expression and Activity in CKD 
No significance differences were observed between groups regarding CYP2B protein 
expression (Figure 3.12A). The conversion of bupropion to OH-bupropion was 
significantly lower in CKD and CKD+AST-120 animals compared to control and 
control+AST-120 (Figure 3.13). Calculation of Michaelis-Menten parameters and 
subsequent analysis with a one-way ANOVA and Tukey’s Post-hoc test revealed 
differences with maximal enzyme velocity (Vmax), Km, and intrinsic clearance between 
groups (Figure 3.14, Table 3.1). CKD and CKD+AST-120 had a significantly lower Vmax 
when compared to control and control+AST-120 (p<0.0001 and p<0.01 respectively). 
Enzyme affinity was shown to be lower in CKD and CKD+AST-120 when compared to 
control and control+AST-120 as the Km was higher (p<0.0001). Intrinsic clearance of 
bupropion was shown to be significantly lower in CKD and CKD+AST-120 when 
compared to control and control+AST-120 (p<0.0001).  
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Figure 3.12 - A) Relative protein expression of CYP2B from an 8-week model of CKD 
in wistar rats. Control, control+AST, CKD and CKD+AST-120 groups are presented as 
mean ± SEM, n=9-12 per group. β-actin was used as the housekeeping gene. (B) 
Representative blots with LC= Loading Control, C=Control, C+A=Control+AST-120, 
CKD+A=CKD+AST-120, CKD=CKD. 
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Figure 3.13 - Bupropion metabolism to OH-bupropion as a measure of CYP2B activity 
in rat liver microsomes from control, control+AST-120, CKD, and CKD+AST-120 
animals. Vmax and Km were determined using the Michaelis-Menten model. They were 
further analyzed using column statistics and an ordinary one-way ANOVA with Tukey’s 
post-hoc test, n=9-12 per group and *P <0.05. Vmax was significantly higher in control 
and control+AST-120 as compared to CKD and CKD+AST-120 while Km followed the 
opposite trend of being lower in control and control+AST-120 as opposed to CKD and 
CKD+AST-120. 
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Figure 3.14 - Michaelis-Menten parameters derived from figure 3.13 and displayed as 
Vmax (A), Km (B), and intrinsic clearance (C). Control, control+AST, CKD and 
CKD+AST-120 groups are presented as mean ± SEM, n=9-12 per group, ****p<0.0001, 
††p<0.01, ††††p<0.0001. Vmax and intrinsic clearance in CKD and CKD+AST-120 animals 
were significantly lower than control and control+AST-120. The Km in CKD and 
CKD+AST-120 rats was significantly greater than control and control+AST-120. * is 
relative to control, † is relative to control+AST-120. 
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Sample Model 
Equation 
Km (M) Vmax (pmol/min/mg 
CYP) 
Control Michaelis-
Menten 
60.342.615 60.68 3.713 
Control+AST-
120 
 72.138.303 52.234.469 
CKD  312.230.29 32.662.654 
CKD+AST-120  303.239.24 35.453.546 
Table 3.1 - Michealis-Menten parameters for Km and Vmax pertaining to the data in Figure 
13. Values are presented as mean  SEM. 
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3.3.5 mRNA Expression of Nuclear Receptors and ChIP for 
CYP2B 
The transcriptional expression of hepatic CAR and RXR were evaluated and showed no 
differences between groups (Figure 3.15). The binding of RNA polymerase II to the 
CYP2B1 promoter was not different between control, CKD, or IgG groups (Figure 
3.16A). The positive control was RNA polymerase II binding to the CYP3A2 promoter, 
which showed a significant decrease (p<0.05) in CKD compared to control (Figure 
3.16B).  
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Figure 3.15 - Relative mRNA expression of hepatic transcription factors in an 8 week 
model of CKD. Graphs A and B display control, control+AST, CKD and CKD+AST-120 
in wistar rats. Presented as mean ± SEM, n=9-12 per group. β-actin was used as the 
housekeeping gene for CAR (A) and RXR (B). 
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Figure 3.16 - Binding of RNA Polymerase II to hepatic CYP2B1 (A) and CYP3A2 (B) 
promoters in an 8 week model of CKD. Graphs A and B display control and CKD RNA 
Polymerase II binding as well as pooled IgG pulldowns from ChIP performed in tissue 
from male wistar rats. Presented as mean ± SEM, n=4-6 per group, *p <0.05. All genes 
were normalized to RNA Pol II binding to GAPDH. RNA Polymerase II binding to the 
3A2 promoter in CKD animals was significantly lower than those from control, 
according to Tukey’s post-hoc test.   
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3.4 Uremic Toxins as a Mechanism of Down-Regulation in 
vitro 
3.4.1 Huh7 Cell Line Validation 
Expression of hepatic transporters normalized to 18s rRNA in both human liver samples 
and Huh7 cells were comparable to previously reported levels by Sivertsson et al in 2010 
(Figure 3.17). The expression of OATP1B1 was 63.5% lower in Huh7 cells compared to 
human livers. The expression of NTCP was 58.5% higher in Huh7 cells compared to 
human liver controls. The expression of BCRP was 97.2% lower than normal human 
hepatic levels.   
3.4.2 Rosuvastatin Uptake 
Co-incubation of Huh7 cells with rosuvastatin and various uremic toxins showed no 
difference from control in regards to intracellular rosuvastatin concentrations (Figure 
3.18). Pre-incubation of the cells with uremic toxins for 2 hours followed by a co-
incubation with rosuvastatin and the same toxins resulted in no differences from control 
except for wells treated with CMPF (Figure 3.19). CMPF was significantly higher than 
control levels (p<0.05) with a 50% increase in rosuvastatin uptake. The positive control 
of 100µM rifampin showed a significantly lower (p<0.01) intracellular concentration of 
rosuvastatin compared to control levels.  
3.4.3 CYP2B6 Expression 
Uremic toxins did not cause any significant differences in the expression of CYP2B6 
mRNA expression using Dunnett’s multiple comparisons test (Figure 3.20).  
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Figure 3.17 - Huh7 cell line characterization. Expression of mRNA is relative to human 
liver for each transporter. 18S rRNA was used to control for individual sample RNA 
expression levels. 
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Figure 3.18 - Rosuvastatin uptake in Huh7 cells after co-incubation with various 
uremic toxins. The cocktail was a combination of all uremic toxins presented. 
Analyzed using ordinary one-way ANOVA with Dunnett’s Post-hoc test. Presented 
as mean  SEM, n=3 per group. 
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Figure 3.19 - Rosuvastatin uptake in Huh7 cells after pre and co-incubation with 
various uremic toxins. The cocktail was a combination of all uremic toxins presented 
except phenyl sulfate and 4-ethyl phenyl sulfate.  Analyzed using ordinary one-way 
ANOVA with Dunnett’s Post-hoc test. Presented as mean  SEM, n=3 per group, 
*p<0.05, **p<0.01. 
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Figure 3.20 - CYP2B6 mRNA expression in Huh7 cells after a 24 hour incubation 
with various uremic toxins. Presented as mean ± SEM, n=3 per group. DMSO 
served as the vehicle control. The cocktail included all the uremic toxins presented 
in the figure at their respective concentrations. 
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Chapter 4  
4 Discussion 
There has been a recent emergence of studies evaluating the effect of chronic kidney 
disease on drug transport and metabolism. This stems from the increasing prevalence of 
the disease and the numerous comorbidities that follow its onset. The glaring 
repercussion of multiple severe comorbidities is that there will be a need for prescriptions 
of a multitude of drugs in order to combat the extensive pathogenic symptoms. This is 
typical for CKD patients, and this alone can cause drug-drug interactions and adverse 
drug reactions. To make matters worse it is well understood and obvious that the renal 
excretory pathway is compromised in CKD, meaning altered drug pharmacokinetics will 
be abundant and need to be accounted for. This has been included in a draft to be 
implemented into the Food and Drug Administration’s guideline for drug development 
(FDA 2010). What has piqued the interest of investigators recently is the impairment of 
hepatic and enteric drug transport and metabolism. This will clearly have a large effect on 
drug kinetics as well since the majority of currently marketed drugs are metabolized in 
the liver and enteric uptake is necessary for most orally administered drugs to exert an 
effect.  
The current putative mechanism for the altered function and expression of hepatic and 
enteric metabolism and transport revolves around the uremic condition that is secondary 
to the loss of renal function (Nolin, 2008; Velenosi et al., 2012; Naud et al., 2012). 
Studies have shown how inflammatory reactions and cytokines are capable of affecting 
CYP expression and function, however it is believed that the accumulated metabolites 
and molecules in uremia play a larger role in CKD patients (Abdel-Razzak et al., 1993; 
Nolin et al., 2008).  In this project we have removed gut-derived uremic toxins in order to 
elucidate whether they play an integral role in hepatic transport and metabolic 
irregularities. The oral adsorbent AST-120 fulfills this objective and is a drug that is 
prescribed to slow the progression to ESRD in Japan. AST-120 was employed in a rat 
model of CKD, induced by 0.7% adenine. To further uncover the role of uremic toxins in 
the alteration of hepatic transport, a study in the human hepatoma cell line was conducted 
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with the implementation of incubation periods with individual uremic toxins and a probe 
for transport activity.  
4.1 Conclusions 
4.1.1 Drug Transport in a 7-week Model of CKD 
Due to the large increases in serum urea and creatinine there is sufficient evidence to say 
that the wistar rats indeed had CKD induced by adenine using the 7-week protocol. 
Contrary to our hypothesis however we did not notice changes in the transcriptional 
expression of hepatic transporters, including Ntcp, P-gp, and Oatp1b2. The assessment of 
the transcriptional expression of these genes in CKD is novel in the literature. The 
translational expression and activity of P-gp has been evaluated previously and has been 
showed to be up-regulated in CKD (Naud et al., 2008). Our results showed no significant 
difference in transcriptional expression between CKD and control for P-gp, although 
there was a 6.4 fold increase in CKD, which aligns with the aforementioned study. The 
CKD+AST-120 group was 36% lower than CKD, possibly implying a partial role of 
uremic metabolites in the upregulation of P-gp and could warrant further investigation.  
The mRNA expression of enteric transporters P-gp, Bcrp, and Mrp2 were unchanged 
from control in our study. A previous study has shown enteric P-gp and Mrp2 to have 
diminished activity and decreased translational expression in CKD (Naud et al., 2007). 
This discontinuity may suggest that only translation and downstream propagation are 
affected or it may be due to differences in the model used as the previous study employed 
a 5/6 nephrectomy to induce CKD. 
Prior to starting formal experiments, I performed initial work on hepatic Oatp1a4 in 
tissue obtained from another student in our lab. This demonstrated a very promising 
result as we saw a significant decrease in Oatp1a4 mRNA expression in CKD animals 
with a subsequent recovery in those treated with AST-120 (Figure 3.10). This was found 
in rats that were subject to the 8-week protocol, however, the level of CKD in this model 
led to the need for premature euthanasia for multiple animals and therefore loss of power 
for the study. We devised the 7-week model due to the irreversible kidney damage 
incurred by week 4 on the 0.7% adenine diet, and with the expectation that it would cause 
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a similar level of kidney damage while improving mortality rates (Tamagaki et al., 2006; 
Hewitson et al., 2008). Hepatic Oatp1a4 showed no difference in transcriptional 
expression and the transport of rosuvastatin was unimpaired in the 7-week model. Due to 
its correlation with decreased kidney function and reports on decreased translational 
expression, we deemed it worthwhile to further pursue this in a more severe model of 
CKD (Naud et al., 2008). Based on the results the previous 8-week protocol provided, we 
decided that a more severe level of CKD would help to test our hypothesis. 
4.2 Drug Transport in an 8-week model  
Again the plasma markers of CKD indicated that the model was sufficient to induce 
severe kidney damage. The transcriptional expression of Oatp1a4 was decreased by 50% 
and showed a significant difference from control animals. Interestingly the animals from 
the CKD+AST-120 groups showed no significant decrease compared to control. This 
suggests the Oatp1a4 down-regulation may be mediated by uremic toxins that are 
removed by AST-120. Although both 8-week animal studies showed no difference 
between control and CKD-AST, one did display a 46.5% decrease in expression. Further 
studies in this area may be necessary for a definitive result as to the role of uremic toxins 
on the impairment of Oatp1a4 transcription.  
The transport of rosuvastatin was not significantly different between groups for the 7-
week or 8-week model of CKD. This evidence is not conclusive to state that the activity 
of Oatp1a4 is not decreased in CKD however. Although Oatp1a4 has a high affinity for 
rosuvastatin, Oatp1a1, Oatp1a5, and Oatp1b2 all have affinity for it as well (Ho et al., 
2006). Due to the empirical evidence that the Oatp1a4 transcript and protein expression 
are decreased there is reason to believe that the activity is affected too, however, it is not 
seen with rosuvastatin as a probe because there may be compensation by the unaffected 
Oatps. Oatp1a1 was also significantly decreased in CKD, but we speculate that Oatp1a5 
and Oatp1b2 are compensating for the transport due to their lack of significance between 
groups. Oatp1a5 was expressed at 43% relative to control despite a lack of significance, 
but Oatp1b2 was expressed at 130% of control and may be the main compensatory 
transporter. Oatp1b2 is also considered a rat orthologue of human OATP1B1 and 
OATP1B3 (Cattori et al., 2000; Smith et al., 2005; Knauer et al., 2010). The liver to 
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plasma concentration of rosuvastatin showed a twofold increase between CKD and 
control suggesting that the uptake is not being impeded, but it may in fact be the efflux of 
rosuvastatin that is altered. We subsequently analyzed the main rat efflux transporter for 
rosuvastatin, Bcrp. The mRNA expression patterns for Bcrp did not explain the increases 
in the liver to plasma ratio as it was only decreased in the groups that received AST-120. 
This is an interesting finding and may suggest that there is a low molecular weight (100-
10000Da) mediator for Bcrp expression in the gut that is being removed by AST-120. It 
is most likely present in both control and the pathological CKD condition as the decrease 
in expression is seen in both control+AST-120 and CKD+AST-120 treatments. This 
warrants further exploration.  
4.3 Altered Expression and Function of CYP2B 
We observed a significant decrease in the transcriptional expression of CYP2B1 in both 
CKD and CKD+AST-120 compared to control. Rats from the control+AST-120 group 
also significantly differed from control in regards to CYP2B1 expression. This pattern is 
similar to that of the expression of Bcrp, where AST-120 administration appears to be 
linked to decreased transcriptional expression. CKD and CKD+AST-120 animals were 
30% and 24% lower than control+AST-120 respectively, suggesting that the pathologic 
state of CKD plays a role in CYP2B1 inhibition. It is unlikely that gut-derived uremic 
toxins are the perpetrator in this instance as there is only a 5.8% recovery in the 
CKD+AST-120 group when compared to CKD. Other potential mechanisms could be 
from the increased levels of middle molecules such as the parathyroid hormone, which 
circulates at higher levels in CKD and as a previous study has shown, it plays a role in 
the downregulation of CYP1A1, CYP2C11, and CYP3A2 (Michaud et al., 2006). 
Cytokines are also middle molecules that have been shown to play a role in the altered 
expression of CYP enzymes as they have increased abundance in CKD (Amdur et al., 
2016). The adenine-induced model of CKD also shows increases in inflammatory 
cytokines (Ali et al., 2016). Increased cytokine production increases the activity of 
inducible nitric oxide synthase, which in turn increases nitric oxide output, this has been 
shown to downregulate CYP expression and function (Abdel-Razzak et al., 1993; Aitken 
et al., 2006; Morgan et al., 2008). A study from 1996 describes the role of nitric oxide in 
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the down regulation of CYP2B1 and CYP2B2 in rat primary hepatocyte cultures (Carlson 
and Billings, 1996). Treatment with TNF𝛼, IL-1β, and IFN-𝛾 (all increased in CKD) 
caused high levels of nitric oxide self-generation in the culture and subsequent loss of 
total CYP expression with the most affected isoenzymes being CYP2B1 and CYP2B2 
(Carlson and Billings, 1996). Nitric oxide synthase inhibitors attenuated this 
downregulation, suggesting nitric oxide may be responsible (Carlson and Billings, 1996).  
CKD patients typically do not have high systemic nitric oxide levels however, nitric 
oxide synthase is impaired by asymmetric dimethylarginine and potentially indoxyl 
sulfate, two abundant uremic toxins (Figure 4.1) (Baylis, 2008). Treatment with AST-120 
has been shown to increase nitric oxide levels through the removal of indoxyl sulfate 
(Niwa, 2013). Inflammatory factors increase the hepatic production of nitric oxide 
through inducible nitric oxide synthase, therefore causing potentially inhibitory levels of 
nitric oxide with persistent inflammation (Aitken et al., 2006; Niwa, 2013). TNF𝛼 and 
IL-1β may play independent roles in the decrease in CYP2B1 transcription as well, as 
they are upregulated in CKD as well as in the adenine induced model of CKD (Morgan et 
al., 2002; Aitken et al., 2006; Ali et al., 2016).  
The translational expression of CYP2B was unaffected between groups. This is likely due 
to the lack of specificity of the antibody and the inherent difficulty of separating proteins 
with 97% sequence homology using antibody based techniques (Pekthong et al., 2012). 
We believe the result shows no difference because the expression of CYP2B2 in CKD is 
unchanged and may be masking the decrease in CYP2B1. To further investigate this we 
looked at the activity of CYP2B1 using bupropion metabolism as a selective marker for 
enzyme function (Pekthong et al., 2012). CYP2B1 is considered more catalytically active 
and we have shown decreased mRNA expression in CKD so we decided to focus on it 
(Pekthong et al., 2012). The conversion of BUP to OH-BUP showed differences between 
control and control+AST-120 when compared to CKD and CKD+AST-120. The 
decreased Vmax and intrinsic clearance suggests that CYP2B1 activity is impaired. The 
pronounced increase observed in Km suggests that there are other CYP enzymes playing a 
part in OH-BUP production. The residual metabolic function and the respective Km is 
indicative of the affinity of CYP2E1 for BUP. CYP2B1 is responsible for 75% of OH- 
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Figure 4.1 - Proposed mechanism for the decreased mRNA expression and function of 
CYP2B1 in CKD. 
84 
 
BUP formation and CYP2C11 accounts for 8.7% as noted by Pekthong and colleagues in 
2012. In the present study we have shown that CYP2B1 expression is decreased and 
likely its function too. CYP2C11 has been shown to have a significant loss of function in 
CKD as well (Leblond et al., 2000; Velenosi et al., 2012). CYP2E1 normally accounts 
for 10.9% of BUP metabolism and is likely responsible for the residual creation of OH-
BUP seen in the CKD and CKD+AST-120 groups (Pekthong et al., 2012). The mRNA 
and protein expression of CYP2E1 are not affected in primary rat hepatocytes incubated 
with serum from uremic patients for 24 hours which likely means its activity is preserved 
in CKD (Michaud et al., 2005). 
The impairment of CYP2B1 activity in CKD is probably not due to gut-derived uremic 
toxins as no recovery was observed when animals were treated with AST-120. A putative 
mechanism may be inhibition due to reactive oxygen species, high levels of pro-
inflammatory markers, and subsequent nitric oxide production through inducible nitric 
oxide synthase. A study has shown peroxynitrite is able to cause nitration of tyrosine 
residues in CYP2B1, conferring a loss of function of the protein (Roberts et al., 1998). 
Peroxynitrite is high in CKD conditions due to excessive superoxide levels reacting with 
nitric oxide and subsequent production of peroxynitrate (Zalba et al., 2006). 
The next step in the assessment of the down regulation of CYP2B1 in CKD was to 
evaluate the nuclear regulation. The mRNA expression of CAR and RXR showed no 
difference between groups so we moved to ChIP in an attempt to examine whether CAR 
or RNA Pol II binding were altered in the PBREM promoter region. We again saw no 
difference between groups however a concern over the high IgG background signal of the 
experiment was unable to be solved, leaving our data for this experiment inconclusive. 
The positive control of RNA Pol II binding to the CYP3A2 promoter showed the same 
results as previously reported in the literature, decreased binding in CKD (Velenosi et al., 
2014).  
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4.4 Role of Uremic Toxins on Rosuvastatin Transport in 
vitro 
Validation of the Huh7 cell line consisted of a comparison to human liver mRNA 
expression levels. Sufficient OATP1B1 and NTCP mRNA expression was displayed for 
it to be a valid system for rosuvastatin uptake. The main efflux transporter for 
rosuvastatin in humans was not highly expressed in this cell line, suggesting that most of 
the rosuvastatin taken up by the cells will remain internalized, allowing for more accurate 
assessment of uptake.  
No differences were seen between groups for the uptake of rosuvastatin in the Huh7 cell 
line when incubated with various uremic toxins. This study shows that uremic toxins are 
unlikely to cause an alteration in rosuvastatin pharmacokinetics. Neither the specific 
individual toxins or the cocktail of toxins showed a difference with a co-incubation or a 
preincubation with the toxins. There is the possibility that other uremic toxins that were 
not tested may disrupt the activity of OATP1B1 and NTCP but we have been unable to 
show this with the ones we selected. The concentrations for the uremic toxins were the 
highest reported amount recorded from patients in the literature (Vanholder et al., 2003). 
Higher concentrations would compromise the physiological relevancy of the experiment 
and have also resulted in substantial levels of cell death.  
The transcriptional expression of CYP2B6 was unchanged when Huh7 cells were treated 
with various uremic toxins for 24 hours. This is the human orthologue of CYP2B1 and 
CYP2B2 so based on the AST-120 data from the in vivo portion of the study it would be 
reasonable to conclude that the gut-derived uremic toxins are not the direct cause for the 
decreased activity and expression seen in the rats. A study from 2014 strengthens this 
theory as they noticed no difference in CYP2B6 activity when human liver microsomes 
were incubated with serum from CKD patients pre- and post-hemodialysis (Volpe et al., 
2014). Conclusions from this could also be that the uremic toxins are not involved in 
direct inhibition but may play a regulatory role on CYP2B6 expression as it has been 
shown to have a loss of activity in CKD (Turpeinen et al., 2007). This study shows a 66% 
decrease in the conversion of BUP to OH-BUP in renally impaired patients compared to 
control (Turpeinen et al., 2007). The conversion to OH-BUP is a selective marker for 
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CYP2B6 function in humans (Faucette et al., 2000). CYP2B6 is also renally expressed so 
if its hepatic expression is not affected this study’s findings may also be a result of 
impaired renal CYP2B6 (Gervot et al., 1999).  
4.5 Limitations 
We were not able to use absolute quantification of rosuvastatin in the assessment of 
transport function as there were inconsistencies due to human error involving the 
injection of the drug. The liver to plasma ratio controls for this but a direct quantification 
and comparison between matrices would have been more appropriate.  
Uremic toxins other than urea and creatinine were not quantified in this study. The 
increase of gut-derived uremic toxins in CKD and the ability of AST-120 to remove them 
are well described in the literature (Niwa et al., 1991; Yamamoto et al., 2015; Velenosi et 
al., 2016). We believed that the reproducibility of these processes would subvert the need 
to quantify them for the purposes of this project.  
An attempt was made to use fexofenadine as a transporter function probe for the CKD in 
vivo rat model as there have been reports on its clearance decreasing in CKD (Nolin et 
al., 2009; Joy et al., 2014; Thomson et al., 2015). We were unable to achieve adequate 
fexofenadine solubility for the purpose of IV injection in our initial trials. This portion of 
the project was discontinued to focus on rosuvastatin transport and CYP2B.  
Attempts to assess the translational expression of Oatp1a4 were unsuccessful despite 
repeated attempts at various antibody dilutions. The western blots for CYP2B produced 
an unexpected result based on mRNA and activity data. It is most likely because of the 
high sequence homology between CYP2B1 and 2B2 combined with a poor specificity 
antibody (the only one available). There are two bands in some of the lanes when probing 
for 2B1 and 2B2 and this is shown on the antibody product sheet as well. We were unable 
to separate these bands using different voltages and run-times for the gels. We were also 
unable to elucidate which band belongs to which protein as supersomes for CYP2B1 and 
CYP2B2 are not available.  
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The difficulties with ChIP are obvious when looking at our data (Figure 3.16). Due to the 
high sequence homology of CYP2B1 and CYP2B2 (98-100% in the promoter region), it 
was difficult to develop CYP2B1 specific primers. With the limited options available, the 
primer specificity was not optimal. The CAR binding site primer was well designed and 
validated however no signal was observed in any of the replicates of the experiment. This 
may be because of the lack of phenobarbital induction results in no binding of CAR to the 
PBREM. We were unable to acquire phenobarbital induced tissue in order to test this 
theory. A study from 1998 showed that there was constitutive activation of CAR in the 
absence of PB in transformed primary mouse hepatocytes (Honkakoski et al., 1998). The 
same group also points out how this is unusual and may result from incomplete signaling 
pathways or absent inhibitors in the transformed cell line (Honkakoski et al., 1998).   
4.6 Future Studies 
An interesting finding with the administration of the endogenous flavonoid chrysin, 
showed reduced TNF𝛼 in adenine treated rats (Ali et al., 2016). Increased TNF𝛼 is a 
potential factor in the increased peroxynitrite seen in CKD as inducible nitric oxide 
synthase can be activated during an inflammatory response. Peroxynitrite has been shown 
to affect the activity of CYP2B1 (Roberts et al., 1998). Administration of chrysin may be 
able to alleviate the downregulation of CYP2B1 in CKD conditions through the 
amelioration of pathologic nitric oxide species.  
A lot of focus is put on the regulation of CYP enzymes in CKD, a slightly overlooked 
area is the effect of the pathologic state on cytochrome P450 oxidoreductase (POR). POR 
facilitates the transfer of electrons from NADPH to CYP enzymes, providing the 
oxidizing power necessary for metabolism (Jin et al., 2015). Without proper POR 
function the CYP enzymes will be unable to function as efficiently, leading to altered 
metabolism and drug pharmacokinetics. Analysis of POR expression and function in 
CKD could reveal a mechanism for the loss of CYP function.  
Human CYP2B6 has been shown to retain its activity in microsomal metabolism assays 
when incubated with pre and post-dialysis uremic serum (Volpe et al., 2014). Uremic 
serum alone may not encapsulate the inhibitory markers that are responsible for the 
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observed downregulation seen for CYP2B1. Analysis of hepatic CYP2B6 expression and 
function in livers from CKD patients may reveal a result more similar to what we have 
observed in vivo for CYP2B1. 
If hepatic CYP2B6 shows no difference in expression or function in CKD patients 
another avenue to explore would be renal CYP2B6. Bupropion clearance has been shown 
to be decreased in CKD and CYP2B6 is the metabolic enzyme with the highest reported 
affinity for it (Faucette et al., 2000; Turpeinen et al., 2007). To understand how BUP 
pharmacokinetics are altered a logical next step would be to analyze renal CYP2B6. 
Observed changes here could explain the work by Turpeinen et al from 2007. To confirm 
the conclusion that the residual metabolism of bupropion in the rat liver microsomes is 
due to the catalytic activity of hepatic CYP2E1, a metabolism assay using supersomes 
could be completed. Impairment of individual isozymes or the use of Eadie-Hofstee 
analysis could also elucidate which CYP enzyme is responsible for the residual 
conversion of BUP to OH-BUP in CKD conditions.  
The gut microbiome plays an integral role in the propagation of CKD through the 
production of uremic toxins. The administration of AST-120 removes toxins from the GI 
tract to help reduce the effects of the uremic syndrome. It would be interesting to know if 
there is a direct effect of AST-120 on the inhabitants of the gut, if there is any change in 
the enteric milieu for patients taking AST-120 compared to CKD patients who are not.  
The expression of CYP2B1 and CYP2B2 is inducible via PB, this is due to the promoter 
region, PBREM (Czekaj, 2000). It is unknown if CAR binding to PBREM is constitutive 
in the absence of PB. A study to elucidate the binding state of CAR to PBREM in control 
and CKD as well as control+PB and CKD+PB would allow conclusions to be drawn 
about the endogenous interaction of CAR and the PBREM and the regulation of CYP2B1 
and 2B2.  
4.7 Overall Conclusions 
There is an abundance of evidence demonstrating the pharmacokinetics of transported 
drugs are altered in CKD patients. Our animal model did not accurately reproduce 
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previous results as we did not observe any differences in rosuvastatin disposition in this 
study. Future studies are needed in this area but they should pursue alternative methods to 
test this. This is the first report to my knowledge of altered CYP2B1 expression and 
function in CKD. The mechanism of downregulation requires additional investigation as 
our initially proposed pathway did not appear to play a role. Work on hepatic CYP2B6 
from CKD patients should also be completed as I would anticipate it follows a similar 
trend to CYP2B1 in regards to function and expression in CKD. Further knowledge of 
the activity of CYP2B6 in CKD would allow for more informed drug dosing to patients 
in the disease state.  
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